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Chapter 1
Introduction
1.1 Abstract
Age-related macular degeneration and glaucoma are among the most frequent
causes of vision loss in the USA [1]. Like retinitis pigmentosa or diabetic retinopa-
thy, they cause a loss of retinal neurons, that can not be compensated by the
human or mammalian retina. Fish or urodeles (salamander), in contrast, are able
to not only regenerate single cells, but also complete and functioning retinae from
their somatic stem cells. Based on this, many studies aim to clarify the signaling
pathways that lead to regeneration in the retina or that keep the human and
mammalian stem/progenitor cell populations from forming a regenerative reac-
tion.
One pathway that is part of the control mechanism of neural stem cells is the
transforming growth factor (TGF)-β signaling pathway. As TGF-β is known to
reduce neurogenesis in the brain and in neural stem and progenitor cell cultures,
we formed the hypothesis that it also has an influence on the stem/progenitor
cells in the eye.
Focusing on the precursor cells of the retina we were especially interested in
Mu¨ller glia cells, as they present an important stem cell population in fish and
birds.
To demonstrate the influence of the TGF-β pathway on Mu¨ller glia in devel-
oping and lesioned adult mouse eyes, we used mice with a heterozygous deletion
of the promoter region and exon I of Smad7(mothers against decapentaplegic ho-
molog 7) and of exon II of TGF-β Receptor II. With histological and biochemical
methods we could show that a deficiency of Smad7, an inhibitor of the TGF-β
pathway, lead to a thickened inner and outer retina and an elevated number of
Mu¨ller glia in the adult animal, caused by enhanced proliferation in newborn mice.
Interestingly the stem cell marker Nestin could be shown to be elevated in Mu¨ller
glia cells in adult animals as well.
Additionally, we conducted N-methyl-D-aspartate (NMDA) lesions to provocate
a proliferative reaction in the progenitor cell populations of the retina, but no effect
could be shown. Experiments were also done with TGF-β receptor II deficient -
and partly with TGF-β receptor II knockout mice, where a thinned retina in the
adult animals could be found.
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We conclude that TGF-β influences proliferation during the development of the
central retina, but not in the normal or injured adult retina.
1.2 Introduction
Regeneration is a fascinating phenomenon that mankind has been interested in
for centuries. As early as 1768 Lazzaro Spallanzani reported that snails could
regenerate their heads, when decapitated, unfortunately without the brain. This
lead the public to search their gardens for snails, to replicate this experiment
[2]. Many animals in nearly all phyla show these vast regenerative capacities.
Salamanders for example regrow limbs and tails even including the spinal chord,
and planarians are even able to regenerate whole animals from single body parts
[3]. In mammals the regenerative capacities are much more limited, the loss of
cells is often irreparable. This applies in particular to the central nervous system,
about which the neuroanatomist Cajal stated in 1928 [4]: ’Once development was
ended, the founts of growth and regeneration of the axons and dendrites dried up
irrevocably. In adult centers, the nerve paths are something fixed and immutable:
everything may die, nothing may be regenerated.’ In 1962 however the limited
occurrence of new neurons forming in injured adult rat brains was discovered [5].
This sparked new interest in research in the field of regeneration in neural tissues
including the neural retina as part of the brain. The retina is subject to many
degenerative diseases like age related macula degeneration (AMD) or glaucoma,
causing cell loss and leading to considerable visual impairment. Cells that are
lost in these processes in the human retina can not be replaced. Therefore the
study of regenerative processes holds big hopes for the future medical care of these
diseases, most of all, hopes that the process of regeneration can be stimulated in
a clinical setting.
1.3 Stem cells
In order to regenerate, a tissue has several options: the proliferation of differen-
tiated cells, the activation of reserve stem cells, the formation of new stem cells
with a limited capacity for self renewal (progenitor cells) or a combination of
these strategies [3]. For our attempts to manipulate regenerative processes, the
knowledge of stem cells and the mechanisms that control their behavior is the key.
1.3.1 Definition of stem cells
Stem cells have the remarkable potential to develop into many different cell types
in the body, during early life and growth [6].
The following features define a stem cell:
1. Multipotency: The cell is not terminally differentiated and can differentiate
into a variety of cells [7].
2. Self renewal: The cell can proliferate infinitely [7].
3. Each daughter cell can decide if it becomes a stem cell or a differentiated
cell [7], see Fig. 1.1.
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4. Even if stem cells can proliferate infinitely, in unleasioned tissue mammalian
stem cells are predominantly in a quiescent non dividing G0-state [7, 8].
1.3.2 Embryonic versus adult stem cells
There are two basic categories of stem cells: embryonic stem cells and adult or so-
matic stem cells. Embryonic stem cells (ES cells) can divide and give rise to cells
of all three germ layers, the ectoderm, the mesoderm and the endoderm [9]. One
of their defining features is their potential to undergo symmetric cell divisions
without differentiation, in order to produce identical progeny. This function is
also known as self renewal. In contrast, tissue specific adult stem cells are lineage
restricted, give rise to specific cell types and have only limited capacity for self
renewal and differentiation [6, 10–12]. In many tissues the adult stem cells reside
quiescently in so called stem cell niches, and are only activated in case of a lesion.
These niches are specialized microenvironments, that keep the stem cell popula-
tion from premature exhaustion [13]. The microenvironment is also responsible
for the fate of the cells.
1.3.3 Asymmetric cell division
In addition to symmetric division, stem cells can also divide asymmetrically and
form another stem cell and a second cell that will terminally differentiate as de-
picted in Figure 1.1. Theoretically this can be influenced in two ways, by the
microenvironment of the cell or by the cell itself. An example for such an mi-
croenvironment is the basal layer of the epidermis. The cells in this niche only
remain stem cells, if they have contact with the basal membrane [7]. Also Mu¨ller
glia cells in culture only convert to the neuronal lineage in an aggregate culture
under non-adhesive conditions [14]. The other possibility is the control by the cell
itself. The division asymmetry can for example be determined by an asymmetric
distribution of cell components.
1.4 Possible stem/progenitor populations in the eye
Different cell types have been suggested to act as neural progenitors in the adult
mammalian retina. To better understand where these cell populations are located,
a short description of the architecture of the neural retina and its surrounding
tissues is given in the following.
1.4.1 The architecture of the neural retina and its surroundings
The retina has a common architecture in non-mammalian and mammalian species
[15]. It consists of 6 types of neurons and 3 types of glial cells. Two types of these
neurons are the light sensitive photoreceptor cells, so called rods and cones. Their
nuclei are located in the outer nuclear layer, see Figure 1.2. The signal from the
photoreceptors is processed through three types of interneurons: bipolar cells,
horizontal cells and amacrine cells. Together with the nuclei of the Mu¨ller glia
cells, their nuclei are located in the inner nuclear layer. In the outer plexiform
layer the terminals of the rods and cones connect to the horizontal and bipolar
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stem cell
terminally
differentiated
cell
Figure 1.1: Each daughter cell that is born when a stem cell divides can either
remain a stem cell or go on and become terminally differentiated [7].
cells. The cells modify the signals and transduce it to the dendrites of the amacrine
cells and ganglion cells. The amacrine cells further process the incoming signal,
whereas the ganglion cells transduce the signal to the brain.
The retina is separated from the choroid by the retinal pigment epithelium
(RPE). The RPE is a single-layer epithelium of pigmented hexagonal cells. It
is responsible for nourishing the photoreceptors and to recycling their disc mem-
branes. The microvilli of the RPE ensheath the outer segments of the photore-
ceptors to do so.
At the anterior margin, the retina passes into the ciliary body, a structure
responsible for the production of the aqueous humour of the eye. The outer
pigmented layer is continuous with the retinal pigment epithelium, the internal
layer is unpigmented and continuous with the retina.
Possible stem cells reside at three niches in the retina: the ciliary marginal zone,
the retinal pigment epithelium and the Mu¨ller glia cells in the neural retina.
1.4.2 The ciliary marginal zone as a source of progenitor cells
The ciliary marginal zone or circumferential germinal zone is a zone on the anterior
margin of the retina, see Figure 1.3. It exists in fish, amphibia and birds and allows
for life long neurogenesis. The zone was searched for in mammals, and it has been
claimed that retinal stem cells exist in the pigmented ciliary margin were the
border of the iris is attached to the ciliary body. It was stated that stem cells
from this region could be propagated in vitro [17] and form rod photoreceptors,
bipolar neurons, and Mu¨ller glia, but the results are highly controversial [18].
According to Moshiri et al. this region does not appear to play a significant role
in the regeneration of the majority of the retina in vertebrates [19].
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Rod
Cone
ONL
Biopolar cell
Horizontal cell
INL
Amacrine cell
Müller glia cell
GCL
Ganglion cell
RPE
IPL
OPL
Figure 1.2: Schematic architecture of the retina (left): ONL = outer nuclear
layer, INL = inner nuclear layer, GCL = Ganglion cell layer, IPL= inner plexiform
layer, OPL = outer plexiform layer; RPE = retinal pigment epithelium; (drawing
adapted from [16]); Micrograph of the layers of the retina (right).
CMZ
RPE
Müller glia
Figure 1.3: Progenitor cell populations can be found in the ciliary marginal
zone, in the RPE and in the neural retina in the form of Mu¨ller glia cells. The
species for which these cell types are considered to be stem/progenitor cells are
shown as pictograms. As things are now, Mu¨ller glia cells are the most popular
candidates for progenitor cells in the mammalian retina [15].
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1.4.3 The retinal pigment epithelium as a source of progenitor
cells
Urodeles (salamander) regenerate the retina after complete surgical removal from
the retinal pigment epithelium, see Figure 1.3. The residing stem cells lose their
pigmentation, form a new layer and recreate the whole retina, with all its layers,
by recapitulating the sequence of normal histogenesis [20,21]. In chicken a similar
process can be seen, but this is restricted to newborn animals [22].
1.4.4 Mu¨ller glia cells as progenitor cells
Mu¨ller glia as progenitor cells in fish and salamanders
In fish the retina can not regrow when everything but the RPE is removed. Ac-
cordingly, the stem cells appeared to be part of the neural retina [23]. Finally
around 2005 several groups discovered that Mu¨ller cells were the primary source
of regeneration in the fish retina, but rod precursors could also be making a con-
tribution. In uninjured fish retina, the progeny of these progenitor cells are the
rod photoreceptors, but after various lesions Mu¨ller glia in fish undergo a robust
response and give rise to all types of cells including photoreceptors, see Figure 1.4.
In salamanders, on the other hand, Mu¨ller glia are not a source of regeneration.
Unlike fish, they do not add new rods to the retina by slowly cycling Mu¨ller glia
during their life. Due to this, their Mu¨ller glia may have lost their regenerative
capacity and the RPE took over this task [15,24,25].
Mu¨ller glia as progenitor cells in chicken
In newborn chicken, Mu¨ller glia are also a source of regeneration. They are able
to reenter the mitotic cycle after neurotoxic damage with NMDA, progressing
through the S- and M-phase and generating two daughter cells. This process can
be prolonged through the use of growth factors [26].
Unfortunately only a subset of the newborn cells express progenitor markers,
and an even smaller number differentiates into cells that express neuronal markers.
Most of these cells express markers of amacrine cells and of bipolar cells. Ganglion
cells and horizontal cells are also rarely observed, see Figure 1.4, but to date there
is no evidence that these cells are functional.
Just like in fish, retinal damage causes chicken Mu¨ller glia cells to proliferate
and upregulate the expression of neural progenitor genes, but unlike fish cells they
undergo only one round of division, whereas fish Mu¨ller glia undergo multiple
rounds and form small neurogenic clusters [27–32].
Mu¨ller glia as progenitor cells in mammalia
In the mammalian retina the proliferative response is much more limited compared
to fish or birds. After damage, Mu¨ller glia cells mainly get reactive and hyper-
trophic, but only few reenter the mitotic cycle [33]. Nevertheless Sahel et al. and
Ooto et al. could show that in rats a subpopulation of Mu¨ller glia cells could reen-
ter the cell cycle when treated with mitogens and after damage [15,34,35]. Ooto et
al. even showed that 30% of the BRDU labeled cells persisted for at least 28 days.
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The amount of damage appears to be important for the intensity of the regener-
ative response as well. After a heavy damage with MNU (methyl nitrosourea) a
large number of Mu¨ller glia reentered the cell cycle in adult rats [15,36,37].
Beside lesions, growth factors influence the number of BRDU positive cells. For
example Close et al. showed that the treatment of the eye with epidermal growth
factor (EGF) injections increased the number of BRDU positive Mu¨ller glia after
light damage in rats [15,38,39].
The types of neurons that can be generated is also limited in mammals. To
allow for differentiation of Mu¨ller glia progeny into different cell types, Ooto et
al. treated rat eyes with protein kinase C, neuron specific enolase, rhodopsin and
the calcium binding protein - recoverin - after NMDA damage. In this experiment
they could detect markers of bipolar cells and rods in the progeny of Mu¨ller glia
cells [15, 35], see Figure 1.4. An amacrine cell fate could only be promoted in
explant cultures by infecting cells with viruses expressing NeuroD1, Math3 and
Pax6.
To get a regenerative response in mice is even more difficult than it is in rats, but
Karl et al. were able to show that Mu¨ller glia cells in the mouse retina proliferate
after NMDA injection if treated with EGF and fibroblast growth factor (FGF). In
this experiment, a huge amount of Mu¨ller glia were recruited into the mitotic cell
cycle 72 hours after injury and some of the Mu¨ller glia progeny showed markers
of progenitor cells and even of amacrine cells [40]. Figure 1.4 shows which cells
can be regenerated from Mu¨ller glia in different species. The variety of cells that
can be formed from Mu¨ller glia declines from lower to higher developed animals.
1.5 A closer look at Mu¨ller glia cells
1.5.1 Architecture of Mu¨ller glia
Mu¨ller glia cells are radial glia (glia means ’glue’ in Greek) spanning the whole
retina, see Figure 1.2. They are one of three glia cell types in the eye, the other
two are astrocytes - another type of macroglia - and the so called microglia, which
are blood derived resident immune cells. The somata of the Mu¨ller glia cells lie
in the inner nuclear layer. Their processes reach to the ganglion cell layer, where
they border on the vitreous body, and to the outer nuclear layer, where they
ensheath the photoreceptor cell bodies, see Figure 1.5. Each of the Mu¨ller glia
cells is considered as the core of a micro-unit or columnar unit of about 15 retinal
neurons. In this way it works as scaffold and anatomical link for the neurons to
the compartments they exchange molecules with [41].
1.5.2 Mu¨ller glia in development
As the cells are born in the developing retina, single progenitor cells give rise to
Mu¨ller glia cells and retinal neurons [43] in two phases. In the earlier phase, the
cells in the apical margin of the neuroephithelium give rise to cone cells, horizontal
cells and ganglion cells. In the second phase, rod photoreceptors, bipolar cells and
Mu¨ller glia are born, see Figure 1.6. In mice, for example, the differentiation of
Mu¨ller glia occurs approximately between postnatal day 1 and 8 [44].
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Figure 1.4: Cell types regenerated from Mu¨ller glia: The variety of cells that
can be recovered from Mu¨ller glia as progenitor cells after injury declines in higher
developed animals [15]. RGC = retinal ganglion cell; MG = Mu¨ller glia cell; BP
= bipolar cell; AC = amacrine cell; HC = horizontal cell, C = Cone; R = Rod.
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Figure 1.5: (A) Mu¨ller glia are the center of a so called microunit. They provide
a scaffold and nutrition for about 15 neurons surrounding them. R = photore-
ceptor, B = bipolar cell , A = amacrine cell, G = ganglion cell, cap = capillary
(Reichenbach, 1999) .(B) Mu¨ller glia span the whole retina. Their soma lie in the
inner nuclear layer. Their processes reach to the border of the vitreous body and
ensheath the bodies of the photoreceptors with their microvilli [42].
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Figure 1.6: Time course of cell differentiation in the mouse retina. Cell in the
retina differentiate in two phases. Mu¨ller glia and neurons are derived from the
same progenitors in this process [44].
In a later phase of development the neurons have to migrate to their final
positions. Mu¨ller glia cells are thought to guide much of this neuronal migration
with their processes [45].
1.5.3 Functions of Mu¨ller glia
Mu¨ller glia cells have a variety of tasks in the retina, see Figure 1.7. They provide
the metabolic support and nutrition of the neurons, like the delivery of lactate or
pyruvate [46] or the storage of glycogen [47, 48]. They are responsible for potas-
sium [49] and water homeostasis [50] as well as CO2 buffering [51] and contribute
to the neuronal signaling by transmitter uptake [52–54] and recycling [55, 56].
Additionally they are known to protect the retina against oxidative stress [57,58],
to recycle photopigments [59] and release growth factors [60]. Finally they were
even found to act as optical fibers in the retina [61] and contribute to the B-wave
of electroretinograms by regulation of potassium distribution [62–64].
1.5.4 Gliosis
In the event of lesions, Mu¨ller glia cells often react with a so called gliosis. Glio-
sis is an umbrella term for non-stereotypical responses by glia, associated with a
pathological state [15]. In a gliotic reaction Mu¨ller glia cells can show cell hy-
pertrophy, changes in gene expression, changes in morphology or even migration.
Also the expression of glial fibrillary acidic protein (GFAP) is a hallmark of gliosis.
Less often proliferation is part of this response [41].
Gliosis and regeneration are two different types of reaction of the Mu¨ller glia.
This can be seen in the following experiment: Ciliary neurotrophic factor CNTF
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Figure 1.7: Some examples of the functions of Mu¨ller glia cells as mentioned in
the text [60]. Mu¨ller glia cells can even act as optical fibers [61].
is a main factor triggering gliosis and is elevated after neuronal damage. Mouse
models that overexpress CNTF even show gliosis without any damage. Interest-
ingly in damaged chicken retina, the application of CNTF inhibits regeneration
on the basis of Mu¨ller glia, but promotes gliosis [15, 41].
However, these two mechanisms are not exclusive reactions. In fish, for example,
the retina regenerates completely and Mu¨ller glia show hypertrophy and express
GFAP. All in all gliosis is an essential response of the glia in the event of damage.
It provides rapid repair of the retina but is also responsible for the so called glial
scar, which is a barrier for regeneration [15,41].
1.6 The TGF-β pathway
As the purpose of this work was to evaluate the effects of an altered TGF-β
pathway on the stem and progenitor cell populations in the retina, a short overview
about this pathway and its functions are given in the following.
1.6.1 Functions of the TGF-β pathway
Ligands of the TGF-β pathway have multiple and sometimes opposite effects on
cells. Because of this, TGF-β is often called janus-headed. Its effects depend on
the cellular context, the stage of the target cell, the environment in the niche,
and the identity and dosage of the ligand [65]. In embryogenesis it modulates
proliferation, differentiation, developmental patterning and morphogenesis [66–
69]. But it is also responsible for apoptosis, extracellular matrix formation and
angiogenesis [70]. Additionally it plays an important role in disease pathogenesis.
An inappropriate production of TGF-β for example leads to fibrosis, cancer and
disorders relating to cartilage, bone, muscle fat, vessel walls, and the immune
system [71–75].
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1.6.2 TGF-β: a transforming growth factor
The TGF-β family consists of two subfamilies, one including bone morphogenic
proteins (BMPs) and Mu¨llerian inhibitory substance as well as many growth and
differentiation factors (GDF), the other including nodal, myostatin, inhibin and
TGF-β with its three highly homologous isoforms TGF-β 1, 2 and 3 [70, 76–78].
Each of the genes of the three isoforms encodes an inactive precursor protein.
Of the 391 amino acid precursors, the 112 C-terminal amino acids comprise the
mature protein, whereas the N-terminal prodomain is called the latency associated
peptide. In its biologically active form, TGF-β is a homo-dimer consisting of two
peptides each with a size of 12.5 kDa, linked through disulfide bonds [79, 80].
Secreted TGF-β is composed of active TGF-β, covalently bound to the latency-
associated peptide. Both are bound to the latent TGF-β binding protein (LTBP),
which is linked to the extracellular matrix, and in this way stores the whole
complex in the extracellular space and provides a source of readily available ligand
[76, 81]. The latent TGF-β is activated by enzymatic proteolysis, executed by
proteins like thrombin, integrin or plasmin [72,78,82].
1.6.3 The TGF-β/ALK receptors
The active members of the TGF-β family bind to heterometric transmembrane
receptor complexes. The receptors belong to two families of serine/threonine ki-
nases, known as Type I (TGF-β RI or ALK, 53-65 kDA) and Type II receptors
(TGF-β RII, 70-95 kDa) [83–85]. As of now five Type II and eight Type I re-
ceptors, called activin like kinases (ALKs), are known [86]. The TGF-β receptor
Type III (endoglin, betaglycan) is a indirect signaling mediator that influences
the affinity of TGF-β RII for TGF-β 2, whereas TGF-β 1 and TGF-β 3 bind
directly to TGF-β RII.
1.6.4 The TGF-β signaling
As shown in Figure 1.8 the binding of a ligand to the TGF-β RII leads to the
recruitment of a Type I receptor kinase and phosphorylation of its cytoplasmic
glycine serine domains. The phosphorylation activates the C-terminal kinase do-
main of the Type I receptor, which in turn phosphorylates and thereby activates
the so called Smad-proteins [70, 76, 85]. These proteins are transcription factors
and downstream mediators of the TGF-β pathway. Binding of TGF-β and activin
to the receptor leads to phosphorylation of Smad 2,3 at C- terminal serin residues,
whereas binding of BMPs leads to the phosphorylation of Smad 1,5,8. All these
Smads are so called receptor-regulated- or R-Smads.
After phosphorylation R-Smads form a complex with Smad4, a so called Co-
Smad, translocate to the nucleus and act as transcription factors in cooperation
with co-activators and co-repressors to modulate specific genes.
The inhibitory Smads Smad6 and Smad7 modulate the TGF-β pathway and
the BMP pathway via a negative feedback loop. They bind to the activated Type
I receptor in a stable complex and block the phosphorylation of the R-Smads.
By recruiting ubiquitin E3 ligases as Smurf 1 and Smurf 2, they also lead to an
ubiquitination and degradation of the activated type I receptor. Aside from this,
Smad6 and Smad7 also act in the nucleus. They interact with transcriptional
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Figure 1.8: Receptor mediated TGF-β signaling: The TGF-β ligand binds to
TGF-βRII that complexes with and activates TGF-βRI. This induces the down-
stream Smad-mediated signal transduction (Aigner and Bogdahn, 2008).
repressors like histone deacetylases and disrupt the formation of TGF-β induced
R-Smad DNA complexes [78]. A deregulation of Smad7 is known to cause human
diseases such as tissue fibrosis, inflammatory disease or carcinogenesis [78].
A thorough review of this issue can be found in [86].
1.6.5 Structure and regulation of the Smads
All Smads are structurally related proteins that act as transcription factors [84,87].
The Smad proteins possess two domains, Mad homology (MH) domain 1 and 2.
The MH1 domain is located on the amino terminus. It is responsible for the
protein DNA interaction. The MH2 domain sits at the carboxy terminus and is
responsible for the protein-protein interaction [88].
As the effector proteins of the TGF-β pathway, Smads are closely controlled by
ubiquitination [89, 90], changes in dynamics of cytoplasmatic shuttling of Smads
[91], and posttranscriptional modification like acetylation or phosphorylation [92,
93].
1.6.6 TGF-β in embryonic and neural stem cells
Significant for our hypothesis is that the TGF-β pathway plays a major role in
the self renewal of both human and mouse embryonic stem cells [94].
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For example a dramatic decrease of proliferation in cultured mouse ES cells
could be seen, when SB431542, an inhibitor of the type I receptor kinases, and
therefore of the TGF-β signaling, was applied. The pluripotency of the cells was
not influenced by the inhibitor. This suggests that activin, nodal and/or TGF-β
signaling is indispensable for the proliferation of most embryonic stem cells [94].
TGF-β was also shown to have an effect on the differentiation of stem cells:
TGF-β, activin or nodal signaling were observed in undifferentiated human em-
bryonic stem cells and decreased upon early differentiation [95]. An inhibition of
the TGF-β/activin/nodal signaling by SB431542 resulted in decreased expression
of markers of undifferentiated cells [96–98].This suggests that the TGF-β signaling
keeps the cells from differentiating.
For neural stem cells TGF-β is important in maintenance and growth. Ablation
of TGF-β receptor II gene in the mid/hind brain enhanced self renewal but not
multipotency of stem cells, resulting in an enlargement of the mid brain [99] and
Wachs et al. could show that in adult neural stem and progenitor cultures, as well
as after cerebroventricular infusion, TGF-β 1 induced a long lasting inhibition of
proliferation and a reduction of neurogenesis [100].
In vitro TGF-β 1 specifically arrested neural stem and progenitor cells in the
G0/1 phase, but did not affect the self renewal capacity or the differentiation of
the cells [70,100].
Additionally TGF-β determines the fate of stem cells. The inhibition of TGF-β
signaling directs commitment of ES cells to neuroectoderm lineages, resulting in
the formation of embryonic neural stem cells [101].
1.6.7 TGF-β in the retina and in Mu¨ller glia
The TGF-β signaling is also an essential pathway in the retina. For example,
TGF-β receptor I and II are expressed in the rodent retina and are located in the
Nestin positive cells in early development. In later development, they are found
in GLAST positive Mu¨ller glia. The most highly expressed ligand in the retina is
TGF-β 2, which is expressed in inner retinal neurons [102].
Human Mu¨ller glia cells also show the expression of transcripts of TGF-β Type
I and Type II receptors and of TGF-β 1 and 2 [103].
Not much further is known about the effect of the TGF-β pathway on Mu¨ller
glia cells as progenitor cell population in the retina. To test the effect of TGF-β
on Mu¨ller glia proliferation, Close et al. cultured retinal progenitors or Mu¨ller
glia and added dissociated retinal neurons from older rats. This inhibited the
proliferation of the progenitor cells and the Mu¨ller glia. In the presence of the
inhibitor TGFbetaRII-Fc, proliferation was restored [102]. This points to an
inhibitory effect of TGF-β on the proliferation of cultured Mu¨ller glia cells. Close
et al. also showed that the injection of a TGF-β inhibitor into the eye at postnatal
day 5.5 increased the proliferation in the central retina, and when co-injected
with EGF at P10 stimulated the Mu¨ller glia. They conclude that retinal neurons
produce a cytostatic signal that maintains mitotic quiescence in the postnatal
retina [102].
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Figure 1.9: Nestin filaments (green) in a cultured aged Mu¨ller glia cell.
1.7 Nestin
As an important marker for stem and progenitor cells Nestin is often used in
studies of regeneration. As the alteration of the TGF-β pathway influenced the
Nestin expression in our studies, a short introduction to this interesting protein
will be given in the following.
1.7.1 Nestin as a cytoskeletal protein
The cytoskeleton in an eukaryotic cell consists of actin filaments, microtubuli and
intermediate filaments (IF).
Nestin is a member of a large family of more than 50 such intermediate filament
proteins. These proteins belong to 6 classes, see Table 1.1 that divide them
into acidic and basic keratins, lamins, neurofilaments, vimentin like proteins and
Nestin. The structure of intermediate filaments, built by Nestin, can be seen in
Figure 1.9 where a micrograph of the Nestin filaments in a cultured aged Mu¨ller
glia cell is shown.
During the early stages of development Nestin is expressed in dividing cells of
the central nervous system (CNS), the peripheral nervous system (PNS) and in
myogenic tissues. When cells are differentiating, Nestin expression is downregu-
lated, often combined with an upregulation of cell specific intermediate filaments
like Glial fibrillary acidic protein (GFAP) in astrocytes, or alpha-internexin and
neurofilaments in neurons [104].
Interestingly, for an intermediate filament, Nestin can not polymerize by itself.
It prefers to interact with other intermediate filament proteins like vimentin or
alpha internexin [105]. This inability to polymerize is due to a very short N-
terminal ’head’ domain, which in other IF proteins is essential for the assembly of
filaments. The process of assembly and disassembly is closely regulated along with
the cell cycle by the phosphorylation of Nestin [106,107]. The phosphorylation is
placed by the cdc2 kinase which along with Cyclin B constitutes the MPF complex
(maturation/M-phase promoting factor) [108].
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Type group example
Type I and Type II acidic and basic keratins epithelial keratins
Type III vimentin like proteins GFAP, desmin,
vimentin
Type IV neuronal intermediate filaments neurofilaments,
alpha internexin
Type V nuclear lamins lamins
Type VI Nestin Nestin
Table 1.1: Types of intermediate filaments.
1.7.2 Nestin: a marker for neural stem cells
Nestin is widely used as a marker for neural stem/progenitor cells. There are
several findings leading to this.
1. Nestin positive cells are observed in nervous tissue during ontogenesis [109]
and most Nestin positive cells in early development are stem/progenitor
cells engaged in active proliferation [104].
2. Nestin is expressed by neuronal [110] and glial [111] cells as well as by their
common precursors [112–114].
3. Various forms of damage in the brain are followed by the appearance of,
supposedly new, Nestin positive cells [115–118].
4. Stem cells that are transplanted into the nervous system start to express
Nestin [116,119].
1.7.3 Nestin and its role in proliferation and differentiation
Taking a closer look, Nestin appears to have more functions in the retina than
just building the cytoskeleton. Aside from stabilizing cell structure as a cytoplas-
matic protein, Nestin is assumed to be involved in the asymmetric distribution of
material like cytoskeletal proteins or cellular factors in dividing stem cells and in
cytoplasmic trafficking [120], but despite many attempts being made, the in vivo
physiological function of these proteins is widely unknown.
However, there is evidence that Nestin plays an important role in cell prolif-
eration, survival and renewal. It is for example often found in tumors of the
nervous system, like neuroblastomas [121] or gliomas [122]. Additionally a knock-
down in vitro reduces cell growth in cultured neuroblastoma cells and astrocytoma
cells [123,124].
It also appears to play an important role in proper stem cell renewal of neu-
ral stem cells [125]. A knockout of Nestin in mice for example is lethal in the
embryonic stage, and leads to the development of fewer neural stem cells in the
neural tube. Surprisingly this role in self renewal is not coupled to its struc-
tural involvement in the cytoskeleton [125]. There are ideas how Nestin could be
able to modulate the cell cycle, without necessarily being bound to the cytoskele-
ton: Nestin is known to constitute a dynamic scaffold for the Cdk5 signaling
complex [107], a complex responsible for the withdrawal from the cell cycle. In
myoblasts it could be shown that Nestin, interacting with the Ckd5/p35 complex
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as a scaffold protein [126], has the ability to halt the differentiation of myoblasts
in vitro when it is overexpressed. All in all the role of Nestin in controlling the
behavior of stem cells remains to be clarified.
1.8 Aims of my work
The retina is often subject to degenerative diseases like Retinitis pigmentosa,
AMD or glaucoma, leading to cell loss and severe visual impairment. Unlike fish
or urodeles, the adult human retina has no regenerative capacities to compensate
this loss. The control mechanisms of proliferation and regeneration in the retina
are still only poorly understood. A better knowledge of the underlying signaling
pathways would provide the basis for triggering regeneration in a lesioned eyes,
and to replacing lost cells by the body’s own stem/progenitor cells.
One pathway involved in the control of progenitor populations is the TGF-β
pathway. It plays a major role in controlling proliferation and neurogenesis in the
brain. Based on this fact we state the hypothesis, that the TGF-β pathway may
be involved in the control of proliferation and differentiation of the progenitor
cells of the retina, especially of Mu¨ller glia cells, which are part of the stem cells
in fish and birds.
Concordingly the aim of our work is to investigate the influence of the TGF-β
pathway on the proliferation and differentiation in the developing and lesioned
adult retina. To demonstrate effects of an alternated TGF-β pathway on the
morphology of the retina and the proliferation and activation behavior of the
progenitor cells, we use mice with a deficiency in Smad7, an inhibitor of the
TGF-β pathway, and in the TGF-β receptor II. Additionally, with the help of
NMDA lesions we want to examine the effect of the TGF-β pathway on Mu¨ller
glia in case of a lesion in an adult animal.
Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Chemicals and reagents
Chemical Company
1,4-p-phenylendiamin Sigma-Aldrich, Taufkirchen
2-mercaptoethanol Roth, Karlsruhe
10x polymerase chain
Quiagen, Hilden
reaction (PCR)-buffer
agarose Biozym Scientific , Oldendorf
albumin fraction V
Roth, Karlsruhe
bovine serum albumin (BSA)
ammonium peroxodisulfate (APS)
Roth, Karlsruhe
10% weight per volume (w/v)
Ampicillin Serva, Heidelberg
bromophenol blue Sigma-Aldrich, Taufkirchen
cacodylic acid sodium salt Merck, Darmstadt
casyton Roche/Innovatis, Bielefeld
CDP-Star Roche, Mannheim
chloramphenicol Roth, Karlsruhe
chloroform Roth, Karlsruhe
Coomassie R© BrillantBlueR-250 Sigma-Aldrich, Taufkirchen
corn oil Sigma-Aldrich, Taufkirchen
disodium hydrogen phosphate dihydrate Merck, Darmstadt
dimethyl sulfoxide (DMSO) Roth, Karlsruhe
2’-deoxyribonucleotide-
Bioline, Luckenwalde
5’-triphosphate (dNTP)
sodium dodecyl sulfate (SDS) Serva, Heidelberg
Dulbecco’s modified eagle medium PAA, Pasching, AT
epon Serva, Heidelberg
glacial acetic acid Merck, Darmstadt
ethanol, absolute Roth, Karlsruhe
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Chemical Company
ethidium bromide Serva, Heidelberg
fetal calf serum (FCS) Biochrom AG, Berlin
fluorescein Quiagen, Hilden
fluorescent mounting medium DakoCytomation, Hamburg
formaldehyde Roth, Karlsruhe
glutaraldehyde Serva, Heidelberg
glycerin Roth, Karlsruhe
glycine Merck, Darmstadt
Immobilon TM western HRP-substrate Millipore Corp., Billerica, USA
isopropanol Roth, Karlsruhe
potassium dihydrogen phosphate Roth, Karlsruhe
potassium ferricyanide (III) Merck, Darmstadt
potassium ferrocyanide (II), trihydrate Merck, Darmstadt
kanamycin Roth, Karlsruhe
ketamine
Wirtschaftsgenossenschaft
dt. Tiera¨rzte (WDT), Garbsen
magnesium chloride (25mM) Quiagen, Hilden
methanol Merck, Darmstadt
skimmed milk powder Roth, Karlsruhe
methylene blue Roth, Karlsruhe
TEMED
Roth, Karlsruhe
N,N,N’,N’,-tetramethylethylenediamine
sodium chloride Roth, Karlsruhe
Na2HPO4 x H2O Roth, Karlsruhe
sodium hydrogen phosphate monohydrate Merck, Darmstadt
paraformaldehyde (PFA) Sigma-Aldrich, Taufkirchen
phosphate buffered saline (PBS) 1x PAA, Pasching, AT
Peqgold TriFast R©-reagent PeqLab, Erlangen
Penicillin-Streptomycin PAA, Pasching, AT
protease-inhibitor-mix M Serva, Heidelberg
proteinase K Roth, Karlsruhe
Rotiphorese R© Gel 30
Roth, Karlsruhe(30 % acrylamide
with 0.8 % Bi-sacrylamide 5:1)
hydrochloric acid 37 % (HCl) Merck, Darmstadt
SYBR-Green I Quiagen, Hilden
tergitol Sigma-Aldrich, Taufkirchen
tris-(hydroxymethyl-)aminoethan (Tris)
Usb Corp., Cleveland, USA
ultrapure, MB Grade
Tris/HCl Roth, Karlsruhe
Trypsin/EDTA, 0.05 % Invitrogen, Karlsruhe
Triton X-100 Sigma-Aldrich, Taufkirchen
Tween 20 Roth, Karlsruhe
Vectashield mounting medium for
Vector Laboratories,
fluorescence with
Burlingame, USA
4’,6-diamidino-2-phenylindol (DAPI)
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Chemical Company
Water Rotisolv (RNase-free) Roth, Karlsruhe
Xylazin Serumwerk, Bernburg
Table 2.1: Laboratory chemicals.
2.1.2 Laboratory Consumables
Item Company
3MM Whatman paper Neolab, Heidelberg
96-well plates Nunc, Roskilde, DK
adhesive PCR film Peqlab GmbH, Erlangen
Biosphere filter tips Sarstedt, Nu¨mbrecht
CellScraper Sarstedt, Nu¨mbrecht
EasyFlasks Nunclon TM T25, T75 Nunc, Roskilde, DK
glass pipettes Brand, Wertheim
glass ware Schott, Roth, VWR
injection needles VWR International GmbH, Darmstadt
multidishes NuclonTM 6 well Nunc, Roskilde, DK
micro test tubes 0.5 ml, 1.5 ml, 2 ml Roth, Karlsruhe
nitril gloves VWR International GmbH, Darmstadt
Omnifix sterile syringes B. Braun, Wertheim
PCR plates, 96 well iCycler IQ Biorad, Munich
pipette tips Sarstedt, Nu¨mbrecht
reaction tubes 15 ml, 50 ml Sarstedt, Nu¨mbrecht
Rotiprotect latex gloves Roth, Karlsruhe
PVDF western blot membrane Roche, Mannheim
Rotilabo 0.22 µm syringe filter Roth, Karlsruhe
serological pipettes Sarstedt, Nu¨mbrecht
superfrost slides Menzel-Gla¨ser, Braunschweig
disposal bags for autoclavation Sarstedt, Nu¨mbrecht
Table 2.2: Laboratory consumables.
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2.1.3 Laboratory Instruments
Equipment Company
Aida Advanced Image Data Analyzer 4.06 Raytest, Straubenhardt
Axio Imager Z1 Zeiss, Go¨ttingen
Axiovert 40 CFL Zeiss, Go¨ttingen
BioPhotometer Eppendorf, Hamburg
centrifuges 5415D, 5415R, 5804R, 5810R Eppendorf, Hamburg
Casy TT cell counting device Innovatis, Reutlingen
Embedding station HMP 110 (Paraffin) Microm, Waldorf
Hera Cell 150 incubator Heraeus, Hanau
Hera Safe clean bench Heraeus, Hanau
Inolab pH-meter WTW GmbH, Weilheim
Inova 4200 shaker New Brunswick, New Jersey, USA
IQ5 Multicolor Real-time
BioRad, Munich
PCR Detection System + iCycler
Kern PJL 2100-2M analytical balance
Kern & Sohn GmbH,
Balingen-Frommern
LAS 3000 Intelligent dark box Fujifilm, Du¨sseldorf
Mastercycler gradient Eppendorf, Hamburg Wertheim
Mettler AE 163 precision scale balance Mettler Toledo, Giessen
Microm HM 500 OM cryostat Microm International, Walldorf
MilliQ Plus PF purification system Millipore Corp., USA
Model 45-101-i class II
Peqlab GmbH, Erlangen
electrophoresis system
NanoDrop-1000 spectrophotometer Peqlab GmbH, Erlangen
Pipetman pipette Gilson, Middleton, USA
Polymax 1040 shaker Heidolph, Kelheim
Power Shot G5 digital camera Canon, Krefeld
Power Supply Consort, Turnhout, BE
Research pipettes Eppendorf, Hamburg
Semidry electrophoretic transfer cell Peqlab GmbH, Erlangen
Serva-E 25 pump Serva, Heidelberg
Sunrise-Basic enzyme linked Tecan Austria GmbH,
immunosorbent assay (ELISA)-Reader Grodig, AT
Supercut 2050 microtome Reihert-Jung, Kirchseeon
Systec V75 autoclave Systec GmbH, Wettenburg
Thermomixer compact Eppendorf, Hamburg
Vortex Genie 2
Scientific Industries Inc,
New York USA
water bath Memmert, Schwabach
Table 2.3: Laboratory equipment.
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2.1.4 DNA and protein ladders
Item Company
GeneRuler 100 bp ladder Fermentas, St. Leon-Rot
1 kb Ladder New England Biolabs, Frankfurt
PageRulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot
Table 2.4: Protein and DNA - ladders.
2.1.5 Reaction kits
Kit Company
Cell Proliferation ELISA;
Roche applied science
BRDU (colorimetric)
iScriptTM cDNA synthesis kit BioRad, Munich
DeadEndTM Fluorometric TUNEL System Promega
Table 2.5: Reaction kits.
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Figure 2.1: Schematic drawing of the function of the Cre/loxP System (adapted
from [128]).
2.2 Animal models
2.2.1 Animal housing and maintenance
All animals were treated according to the ’ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research’. They were kept at a constant temperature
of 23 ◦C ± 2 ◦C, a humidity of 55 % ± 5 % and were allowed food (standard
laboratory pellets) and water ad libitum. The day-night rhythm was kept at
12/12-hours.
2.2.2 Wistar rats
For primary Mu¨ller glia cell culture 8-12 day old Wistar rats were used.
2.2.3 The Cre/loxP recombination system
To achieve the heterozygous deletions needed to create Smad7 and TGF β RII
deficient mice, the Cre-loxP system was used [127]. This system uses two com-
ponents, see Fig. 2.1: A Cre recombinase that carries out a site specific recom-
bination event, and the loxP recognition sites of this enzyme. The use of certain
promoters for the Cre recombinase allows for tissue specific or induceable removal
of the sequence flanked by the loxP sites. With mouse lines carrying a Cre re-
combinase and others carrying different genes flanked with loxP sites, genes and
Cre recombinases can be combined freely by breeding.
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Figure 2.2: Schematic drawing of the Rosa LacZ mouse construct.
2.2.4 EIIa Cre mice
To achieve the deletion of the floxed sequences in Smad7fl/fl and in TGF-β RIIfl/fl
mice, EIIa Cre mice were used. This mouse line carries the Cre recombinase under
the control of the adenovirus EIIa Cre promoter which targets the expression of
the Cre in the early embryo. It was created by Heiner Westphal [129].
2.2.5 Rosa26 LacZ Reporter mice
This reporter mouse strain, purchased from Jackson labs, expresses β-Galacto-
sidase in cells were a Cre recombinase is activated. The construct, see Fig. 2.2,
contains a Stop sequence flanked by lox P sites. When this sequence is removed
by an active Cre recombinase, β-Galactosidase is expressed and can be detected
by a staining with x-gal in cells and tissue.
2.2.6 CAG Cre ERT - Tamoxifen inducible mice for the breed-
ing of a TGF-β full knockout
The CAG Cre ERT mice have a Tamoxifen-inducible Cre-mediated recombina-
tion system. The Cre recombinase is expressed under the control of the CAG∗
promoter [130], which leads to a ubiquitous Cre expression in case of Tamoxifen
induction. This is done by using a fusion product of the Cre recombinase and a
mutant form of the mouse estrogen receptor. This receptor does not bind estrogen
in physiological conditions but the synthetic ligand 4-hydroxytamoxifen. Before
exposure to Tamoxifen the Cre/Esr1 fusion protein is restricted to the cytoplasm
and can only enter the nucleus and induce the recombination when Tamoxifen is
present. In this work the induction in the retina is achieved by using Tamoxifen
eye drops.
Induction of Cre expression by Tamoxifen eye drops This technique was established
by Sarah Leimbeck and Barbara Braunger (unpublished work). They could show
that the induction of CAG Cre mice with Tamoxifen eye drops, leads to an acti-
vation of the Cre recombinase in all structures of the eye, by using the Rosa LacZ
reporter mouse. The blue LacZ staining of an Tamoxifen treated eye is shown in
Figure 2.3. For the induction of the Cre recombinase Tamoxifen is dissolved in
corn oil in a concentration of 5 mg/ml. The mice are given the solution as eye
drops for 5 days, three times a day, using 10 µl for each eye. Figure 2.3 B shows
∗cytomegalovirus immediate early enhancer-chicken beta-actin hybrid
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:
A B C
Figure 2.3: The induction with Tamoxifen eye drops leads to an expression of
Cre recombinase in all structures of the eye. (A) The photo shows eyes of a CAG
Cre positive and a Cre negative animal after LacZ staining. In the Cre positive
eye, the lens, and even the optic nerve are LacZ positive, whereas the Cre negative
control eye is unstained. (B) Section of a CAG Cre positive eye after Tamoxifen
induction. Every cell in the retina of CAG Cre positive animals is LacZ positive
after induction with Tamoxifen, the CAG Cre negative control can be seen in C
(pictures by B. Braunger and S. Leimbeck).
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Figure 2.4: Schematic drawing of the Smad7fl/fl mouse construct.
that the induction with Tamoxifen eye drops leads to an ubiquitous Cre expression
in the eye, that can be seen by the blue staining caused by the β-Galactosidase
expression.
2.2.7 Smad7fl/fl mice
The Smad7fl/fl mouse strain was generated by Ingo Kleiter et al. [131]. In these
mice the promoter region and exon I are flanked by loxP sites. Figure 2.4 shows
a schematic drawing of the construct.
2.2.8 TGF-β RIIfl/fl mice
In the TGF-β RIIfl/fl mice, exon 2 of the TGF-β type 2 receptor gene was flanked
by loxP sites, see Fig. 2.5. These mice were created by the group of Harold L.
Moses [132].
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Figure 2.5: Schematic drawing of the TGF-β RIIfl/fl mouse construct.
2.2.9 β-B1 CTGF overexpressing mouse strains
These mouse strains, cloned by Junglas et al. [133] express CTGF (Connective
Tissue Growth factor) in the fiber cells of the lens and secrete it into the aqueous
humour. Three different strains were used for this work: Strain 1 with a low
CTGF expression, strain 5 with a moderate CTGF expression and strain 6 with
a high expression. To achieve wildtype littermate controls for the experiments,
heterozygous mice are crossed with FVBN wildtype mice.
2.2.10 Breeding of Smad7fl/− and TGF-β RIIfl/− mice
Breeding of Smad7fl/− mice
To analyze the influence of an increased TGF-β signaling, Smad7 deficient mice
with a heterozygous deletion of the gene were used, as Smad7 is an inhibitor of
the TGF-β pathway. It was not possible to work with a mouse model with a
homozygous deletion of Smad7 in this case, because this proved to be lethal at a
late embryonic stage. Littermates without the deletion of Smad7, but homozygous
for floxsites served as a control.
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Figure 2.6: Breeding procedure for mice with a heterozygous deletion of Smad7
or TGF-β RII ; The EIIa Cre recombinase was eliminated during breeding. The
heterozygous deletion is stably inherited.
To breed the animals, Smad7fl/fl mice were crossed with EIIa-Cre mice, ex-
pressing Cre recombinase ubiquitously under the control of the EIIa-Cre pro-
moter. Figure 2.6 shows the detailed breeding procedure. In the F1 generation,
the progeny was heterozygous for the floxed allele and about half of the progeny
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was carrying the Cre recombinase. Because of the early activity of the recom-
binase, this leads to an ubiquitinous heterozygous deletion of the floxed allele,
including the germline cells of the mice. In this way, the deletion is inherited to
the next generation. By crossing the mice with the heterozygous deletion with
homozygous Smad7fl/fl mice it was possible to get rid of the Cre recombinase
in the F2 generation. Subsequently mice without Cre recombinase and with a
heterozygous deletion of Smad7 were crossed to mice homozygous for Smad7fl/fl
in F3 and the following generations. All experiments were done with Smad7fl/−
and the Smad7fl/fl littermates as a control. The latter are further referred to as
wildtype or wildtype control.
By crossing EIIa Cre animals with the Smad7fl/fl mice, recombination and
deletion of the exon I of Smad7 occurred. This deletion could be detected by
the deletion PCR established by Ingo Kleiter [131], see section 2.3.6. During
breeding, the genetic status was also confirmed by performing PCRs for EIIa
Cre recombinase and for the flox sequences. After the initial phase of breeding,
the animals did not carry the EIIa Cre recombinase anymore, but inherited the
heterozygously deleted sequence.
Breeding of TGF-β RIIfl/− mice
TGF-β RIIfl/− mice were used as a model for reduced TGF-β signaling. To
create a mouse line, comparable to the Smad7fl/− mice, the breeding was done
analogously to that of the Smad7 mice, see above. This breeding lead to a hetero-
zygous deletion of exon II of TGF-β RII. For the experiments, TGF-β RIIfl/−
mice and their littermates carrying floxsites on both alleles (fl/fl) were used. The
latter are called wildtype or wildtype control in the following. For genotyping,
the recombination PCR by Chytil et al. was used [132], see section 2.3.6.
2.3 Genotyping
2.3.1 Extraction of genomic DNA from mouse tails
To gain DNA from mouse tails, the mice were anesthetized with isoflurane. About
0.5 cm of the tip of the tail were cut off with a sterile pair of scissors and transferred
to a 1.5 ml micro test tube. Proteinase K lysis buffer, shown in table 2.6, was
mixed with fresh proteinase K (25 µl per 1 ml lysis buffer) and 200 µl of the
mixture were added to each tail. The mouse tails were incubated at 55 ◦C over
night in a shaker at about 750 rotations per minute (rpm). To inactivate the
enzyme the cups were heated to 95 ◦C and afterwards centrifuged at 16.000 x g
and 4 ◦C for 10 minutes (min). The supernatant was transferred to a fresh cup.
The DNA was stored at -20 ◦C or directly used for PCR analysis.
2.3.2 DNA precipitation
To precipitate the DNA, mouse tail lysate was mixed with 150 µl IRN buffer,
see Table 2.7 and 375 µl of pure ethanol. The mixture was kept at -20◦C for
a minimum of 30 min. After a centrifugation step at 4 ◦C and 14.000 rpm the
supernatant was removed and the pellet was dried for 30 s. The DNA pellet was
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Mouse tail lysis buffer
KCl 50 mM
Tris HCl, pH 8.5 10 mM
MgCl2 2 mM
gelatin 0.1 mg/ml
nonidet P-40 0.45 %
volume per volume (v/v)
tween 20 0.45 % (v/v)
add proteinase K before use 20 mg/ml
Table 2.6: Mouse tail lysis buffer.
solved in 50 µl H2O. If the pellet did not solve properly the sample was incubated
at 37 ◦C and 500 rpm in a thermomixer.
IRN buffer
Tris; 1 M; pH 8.0; 5 ml 50 mM
EDTA; 5 M; 4 ml 20 mM
NaCl; 3 M; 16.6 ml 0.5 M
add H2O ad 100 ml
Table 2.7: IRN DNA precipitation buffer.
2.3.3 PCR - polymerase chain reaction
The polymerase chain reaction is a method developed by K. Mullis [134] to amplify
sequences of DNA. In this work the method is used to prove genetic alterations
like deletions in knockout mouse models.
2.3.4 Genotyping EIIa Cre mice
To create mice mice with a heterozygous deletion, Smad7fl/fl respectively TGF-
β RIIfl/fl mice were bred with EIIa Cre mice. For the genotyping for the Cre
recombinase during the breeding, protocols and programs shown in table 2.8 and
’EIIa cre’ primers, see table 2.15 were used: The PCR shows a band at 700 bp
when the Cre recombinase is present.
2.3.5 Genotyping the Smad7fl/fl and TGF-β RIIfl/fl mice
To check for flox sites during breeding the protocols and programs shown in table
2.9 and 2.10 were used. The PCR gives different sized products depending on the
presence of flox (fl) sites. For the Smad7 mice the wildtype allele gives a signal
at 413 bp, the floxed allele at 568 bp. For the TGF-β mice the band for the
wildtype allele has a size of 556 bp, for the floxed allele it appears at 711 bp. The
glycerol mix needed for this PCR is shown in Table 2.11. The primers used are:
’TGFβRII fl/fl’ and ’Smad7fl/fl’, see Table 2.15.
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genomic DNA (30 ng/µl) 1 µl
10x PCR-buffer 1.5 µl
MgCl2 (25mM) 0.3 µl
dNTPs (10mM) 0.75 µl
Primer forward (fw) (10 µM) 0.6 µl
Primer reverse (rev) (10 µM) 0.6 µl
Taq DNA polymerase 0.4 µl
DMSO 0.75 µl
H2O 9.1 µl
temperature duration
94 ◦C 1 min
94 ◦C 30 s
︸︷︷
︸
37 x57.3 ◦C 30 s
72 ◦C 1 min
72 ◦C 1 min
4 ◦C ∞
Table 2.8: PCR mix and program for EIIa Cre product: 700 bp.
genomic DNA (30 ng/µl) 1 µl
10x PCR-buffer 1.5 µl
MgCl2 (25mM) 0.3 µl
dNTPs (10mM) 0.3 µl
Primer fw (10 µM) 0.3 µl
Primer rev (10 µM) 0.3 µl
Taq DNA polymerase 0.3 µl
5 x glycerol mix 3 µl
H2O 8 µl
Table 2.9: PCR mixes for Smad7 fl/fl; TGF-β RII fl/fl; Smad7 deletion; TGF-β
deletion.
temperature duration
95 ◦C 3 min
95 ◦C 45 s
︸︷︷
︸
35 x63 ◦C 30 s
72 ◦C 45 s
72 ◦C 5 min
4 ◦C ∞
temperature duration
95 ◦C 3 min
95 ◦C 30 s
︸︷︷
︸
35 x61 ◦C 45 s
72 ◦C 1 min
72 ◦C 5 min
4 ◦C ∞
Table 2.10: Left: PCR programs for Smad7fl/fl (wt: 413 bp fl/fl: 568 bp).
Right: PCR programs for TGF-β RIIfl/fl (wt: 556 bp fl/fl: 711 bp).
5x glycerol mix (PCR)
Cresol red 1 mM
glycerol 60%
fill with H2O 40%
Table 2.11: 5x glycerol mix.
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primer
flox-site
PCR product
Figure 2.7: : The primers lie flanking the floxed region. The amplicon is only
short enough to allow for a product when the region between the flox sites is
deleted due to recombination by a Cre recombinase.
temperature duration
95 ◦C 3 min
95 ◦C 15 s
︸︷︷
︸
37 x60 ◦C 45 s
72 ◦C 30 s
72 ◦C 5 min
4 ◦C ∞
temperature duration
94 ◦C 3 min
94 ◦C 20 s
︸︷︷
︸
35 x60.5 ◦C 20 s
72 ◦C 1 min
72 ◦C 5 min
4 ◦C ∞
Table 2.12: PCR program for Smad7 deletion product, 286 bp (left); PCR
program for TGF-β RII deletion, 610 bp (right).
2.3.6 Genotyping the Smad7fl/− and TGF-β RIIfl/− mice by
deletion PCR
To detect the recombination in the Smad7 fl/fl mice and the TGF-β RII fl/fl mice
after crossing them to mice carrying a Cre recombinase, a deletion respectively
recombination PCR was used. For the Smad7 mice this PCR was established
by Ingo Kleiter et al. [131] for the TGF-β RII mice by Chytil et al. [132]. The
deletion PCRs for Smad7 deficient mice and TGF-β RII deficient mice use the
same principle. The primers are chosen flanking the region that is deleted by the
recombination, when the Cre recombinase is active. As primers ’Smad7 recombi-
nant’ and ’TGFβRII recombinant’ forward and reverse, see Table 2.15 were used.
Only if the recombination has occurred, the size of the product that has to be
amplified is short enough for the chosen elongation time of the PCR program, see
Figure 2.7. For the deletion PCR the same PCR mix as for the flox PCRs was
used, see section 2.3.5. The PCR program is shown in Table 2.12.
2.3.7 Genotyping Rosa LacZ mice
To genotype the Rosa26 LacZ reporter mice the protocol and program shown in
Table 2.13 and the Rosa26 LacZ primer shown in Table 2.15 were used. The PCR
results in a 315 bp product for transgenic mice. For the LacZ PCR Bioline Taq
polymerase and Bioline PCR 10x buffer was used.
30 CHAPTER 2. MATERIALS AND METHODS
genomic DNA (30 ng/µl) 2 µl
10x PCR-buffer 2.5 µl
MgCl2 (25mM) 1.2 µl
dNTPs (10mM) 0.5 µl
Primer fw (10 µM) 0.5 µl
Primer rev (10 µM) 0.5 µl
Taq DNA polymerase 0.3 µl
H2O 17.5 µl
temperature duration
94 ◦C 3 min
94 ◦C 30 s
︸︷︷
︸
34 x60 ◦C 30 s
72 ◦C 35 s
72 ◦C 5 min
10 ◦C ∞
Table 2.13: PCR mix and cycler program for Rosa LacZ.
genomic DNA ( 500 ng; 1:20) 2 µl
10x PCR-buffer 1.5 µl
MgCl2 (25mM) 0.3 µl
dNTPs (10mM) 0.3 µl
Primer fw (10 µM) 0.3 µl
Primer rev (10 µM) 0.3 µl
Taq DNA polymerase 0.15 µl
glycerol mix 5x 3.0 µl
H2O 7.15 µl
temperature duration
96 ◦C 2 min
94 ◦C 30 s
︸︷︷
︸
37 x53 ◦C 45 s
72 ◦C 1 min
72 ◦C 5 min
10 ◦C ∞
Table 2.14: PCR mix and Cycler program for SV 40 (CTGF mice), the product
size for transgenic animals is 300 bp.
2.3.8 Genotyping β-B1 CTGF mice
The SV40 primers used for genotyping the CTGF mice recognize the SV40 se-
quence which is inserted into the sequence and derived from Simian virus 40, a
polyomavirus. Transgenic animals show a PCR product with a size of 300 bp.
The PCR mix and cycler program used are shown in Table 2.14. To specify the
sequence that is amplified, the oligonucleotide primer sequences ’SV 40 fw’ and
’rev’ shown in Table 2.15 were used.
2.3.9 Agarose gel electrophoresis
Following the PCR analysis, agarose gel electrophoresis was used to analyze the
PCR products. In this method an electric field drags the DNA fragments through
a molecular net, built by the agarose, to separate the DNA fragments according to
their size. The gel contains ethidiumbromide which is a Phenanthridin-dye that
intercalates in the DNA and fluoresces at 302 nm after excitation. Due to this
the DNA is visible in the gel under UV light.
For the gel mixture 1 g agarose was solved in 100 ml TBE buffer by heating the
solution in a microwave oven. After the solution was lukewarm 3 µl of ethidium
bromide were added, to an end concentration of 30 ng/ml and the gel was poured.
PCR samples that did not contain glycerol mix were mixed with loading buffer,
see table 2.16. Subsequently the gel was put into a buffer chamber filled with
1x TBE, see Table 2.16, and was loaded with 15 µl of every sample. To allow a
correct calculation of the PCR product sizes, a 100 bp DNA standard (NEB) was
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name sequence
Smad7 recombinant fw 5’tgcagacccggaaattagac 3’
Smad7 recombinant rev 5’ ttggatcaccatgccaacta 3’
TGFβRII recombinant fw 5’taaacaaggtccggagccca 3’
TGFβRII recombinant rev 5’agagtgaagccgtggtaggtgagcttg 3’
EIIa Cre fw 5’atggtgtttgagtggttatg 3’
EIIa Cre rev 5’attgcccctgtttcactatc 3’
TGFβRIIfl/fl fw 5’ gcaggcatcaggacctcagtttgatcc 3’
TGFβRIIfl/fl rev 5’ agagtgaagccgtggtaggtgagcttg 3’
Smad7fl/fl fw 5’gtcaggttggatcaccatgcc 3’
Smad7fl/fl rev 5’ gactgcctggagaagtgtgtc 3’
SV 40 fw 5’gtgaaggaaccttacttctgtggtg 3’
SV 40 rev 5’gtccttggggtcttctacctttctc 3’
Rosa26 LacZ fw 5’ atcctctgcatggtcaggtc 3’
Rosa26 LacZ rev 5’cgtggcctgattcattcc 3’
Table 2.15: Genotyping primers.
loading buffer
bromophenol blue 0.25 % (w/v)
xylene cyanol FF 0.25 % (w/v)
ficoll 15 % (w/v)
TBE 10x
TRIS 108 g
borate 55 g
EDTA(0.5 M), pH 8 40 ml
solve in H20 destilled (dest.) ad 1 l
Table 2.16: Buffers for gel electrophoresis.
loaded at one position in each row. Subsequently the gel was run at 120 V for
45 min and the detection was done by the use of an UV lamp.
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2.4 Histology and Immunohistochemistry
2.4.1 Buffers and equipment for histology
Reagents Company
acetone Merck, Darmstadt
lead citrate Merck, Darmstadt
Cacodylic acid sodium salt trihydrate Merck, Darmstadt
2-Dodecenylsuccinic-acid-anhydride (DDSA) Merck, Darmstadt
2,4,6-Tri(dimethylaminomethyl)
Serva, Heidelberg
Phenol (DPM-30)
epon Serva, Heidelberg
glutaraldehyde Serva, Heidelberg
glycidic ether Merck, Darmstadt
isopropanol Roth, Karlsruhe
MNA Carl Roth GmbH, Karlsruhe
osmium tetroxide Merck, Darmstadt
paraffin Engelbrecht, Mu¨nchen
paraformaldehyde Merck, Darmstadt
1,4-p-phenylendiamin Sigma, Taufkirchen
Pioloform Plano, Marburg
uranyl-acetate Merck, Darmstadt
embedding station EM TP (Epon) Leica, Wetzlar
embedding station HMP110 (Paraffin) Microm, Waldorf
slotgrids Plano, Marburg
Supercut 2050 (Paraffin) Reichert-Jung, Kirchseeon
Ultracut E-ultramicrotome (Epon) Reichert-Jung, Kirchseeon
Table 2.17: Chemicals and equipment for histology.
2.4.2 Tissue preparation
Perfusion To prevent artifacts in some immunostainings a perfusion through the
left heart-ventricle was performed. This technique was used primarily for the
BRDU immunostainings of adult mice because of artifacts to stained blood vessels.
For this purpose a 10 ml syringe with a 23G butterfly needle ECOFLO R© was used.
Prior to perfusion the mice were deeply anesthetized with a mixture of xylazin
(6 - 8 mg/kg bodyweight) and ketamin (90 - 120 mg/kg bodyweight) through
intraperitoneal injection. For an easy access to the organs the mice’s limbs were
fixed with needles to a Styrofoam plate. Afterwards the abdomic and thoracic
cavity was opened and the heart was exposed. The butterfly needle was inserted
into the left ventricle and a cut into the vena jejunales or ileales was performed.
Subsequently the animal was slowly perfused with about 8 ml room temperature
PBS heparin solution, see table 2.18, until the fluid leaving the mesenterical veins
was clear. Afterwards the syringe was changed and the animal was perfused with
8 ml ice-cold 4 % paraformaldehyde (PFA). After the perfusion was complete the
eyes were removed and incubated in 4 % PFA for additional 4 h.
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Heparin-solution
PBS 50 ml
Heparin-Natrium 250000 IE 100 µl
Table 2.18: PBS heparin solution.
Eye preparation for embedding and sectioning After an isoflurane anesthesia with
isoflurane the mice were killed by cervical dislocation and eyes were enucleated by
curved forceps without crushing the optic nerve. To allow the fixation medium to
permeate the eye, the cornea was perforated by a small cut. Depending on the
use of the material for paraffin-, epon- or cryo embedding, different fixation media
were used for incubation.
Buffer I : 0.1 M Na2HPO4 x 2 H2O 35.6 g in 2 l H2O
Buffer II : 0.1 M NaH2PO4 x 2 H2O 13.8 g in 1 l H2O
phosphate buffer Buffer I : Buffer II
5:1
pH 7.4
4% Paraformaldehyde 100 ml phosphate buffer
fixation solution (4% PFA) 4 g formaldehyde
30% Sucrose solution 150 g sucrose
500 ml phosphate buffer
Table 2.19: Buffers and solutions used for cryo embedding and immunohisto-
chemistry.
Cryo embedding and sectioning For cryo embedding, the enucleated eyes were
fixated for 4 h in 4 % paraformaldehyde fixation solution (4 % PFA). The ex-
act composition of the buffers used is shown in Table 2.19. Subsequently the
eyes were washed 3 times for 5 minutes with phosphate buffer. To avoid cell
damage by freezing, the eyes were incubated in sucrose solutions with ascending
concentrations (10 %, 20 %, 30 %) each for 4 hours at room temperature or over
night at 4 ◦C. The eyes were embedded in Tissue-Tek R© and frozen directly on the
sample holder in the cryostat to ensure the right adjustment of the sample. Sec-
tions, 12 µm in thickness, were made with the Microm HM 500 OM. To mount
the sections SuperFrost R© slides were used. The sections were used directly for
immunohistochemical staining or stored at -20 ◦C.
Paraffin embedding and sectioning For the paraffin embedding the eyes were fix-
ated for 4 h with 4% PFA and washed 3 times for 5 minutes with phosphate buffer.
To embed the tissue into paraffin it had to be dehydrated: The embedding was
done by the embedding station HMP110 using the following protocol.
• 70% isopropanol ; 1 h
• 80% isopropanol ; 1 h
• 96% isopropanol ; 1 h
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• 96% isopropanol ; 2 h
• 100% isopropanol; 1 h
• 100% isopropanol; 1 h
• 100% isopropanol; 2 h
• 100% xylene ; 1.5 h
• 100% xylene ; 2 h
• paraffin ; 4 h
• paraffin ; 8 h
Sagittal sections approximately 6 µm in thickness were produced using the
Supercut 2050-Microtome.
Dewaxing and rehydration To prepare the paraffin sections for staining they were
dewaxed and dehydrated as the following protocol shows.
• 2x 100% xylene; 10 min
• 2x 100% isopropanol; 10 min
• 2x 96% isopropanol; 5 min
• 2x 80% isopropanol; 5 min
• 1x 70% isopropanol; 5 min
• H2O dest.; 5 min
Epon embedding and sectioning To measure retinal thickness and determine the
number of axons in the optic nerve, epon semithin sections were used. For epon
embedding the eyes had to be fixated for 12 h in EM fixation medium; see Table
2.20. After 4 x 20 min washing steps with cacodylate-buffer the eyes were fixated
with 1 % osmium tetroxide. To remove the osmium tetroxide, eyes were washed
with cacodylate-buffer and dehydrated using ascending alcohol-concentrations
(ethanol 70%, 80%, 90%, 100%). The embedding was done with the help of
an embedding station with the following protocol: Ethanol/acetone 1:1; 100 %
aceton; epon/acetone 1:2; epon/acetone 2:1; To harden the samples they were
incubated for 24 h at 60 ◦C and for 48 h at 90 ◦C. Epon itself is a 1:1 mixture of
stock solution A and stock solution B containing 2 % DMP-30 as accelerator; see
Table 2.20.
2.4.3 Histological stainings
The Richardson staining
Sections for measurement of retinal thickness were stained using the Richardson
method [135]. The sections were incubated with Richardson’s solution, see Table
2.21, for 15-30 seconds at 60 ◦C. The solution was removed by a washing step
with H2O dest..
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buffer compounds
cacodylate buffer 20.14 g cacodylic acid
0.5 l H2O dest.
pH 7.2
EM fixation medium 2.5 % paraformaldehyde
2.5 % glutaraldehyde
in cacodylate buffer
stock solution A 62 ml glycidether
100 ml DDSA
stock solution B 100 ml glycidether
89 ml MNA
Table 2.20: Buffers and solutions for Epon embedding.
buffer compounds
stock solution I 1 % Azur II in 500 ml H2O dest.
stock solution II 1 % Methylenblue in 500 ml 1 % Borax
Richardson’s solution 1:1:2
stock solution I: stock solution II: H20 dest.
Table 2.21: Solutions for Richardson’s staining.
Paraphenylendiamin staining for axon counting of optic nerves
To stain optic nerves, 500 mg Paraphenylendiamin were dissolved in 50 ml ethanol.
Three days at daylight lead to oxidation of the solution causing a brown color.
The semithinsections were stained with this solution for 2-3 minutes followed by a
washing step with ethanol. The sections were evaluated by light microscopy and
the axons were counted manually using Photoshop CS3.
2.4.4 Measurement of retinal thickness
For the measurement of the retinal thickness, 3 week old mice were killed and
their eyes were embedded in epon as shown in section 2.4.2. Sagittal sections,
1 µm in thickness, containing the optic nerve and the papilla were stained with
the Richardson method see section 2.4.3. The light microscopic images were used
to measure the thickness of the retina with the help of the Axiovision software
from Zeiss. For a comparable measurement of all eyes, the length of the retina was
measured along the outer nuclear layer (ONL) and each side of the optic nerve was
divided into 10 parts of equal length which leads to 9 measurement points along
the retina as shown in Figure 2.8. The thickness of the retina at the optic nerve
and the ora serrata was assumed to be zero. The measurements of both sides of
the retina were averaged. For the detailed measurement of the inner nuclear layer
(INL) the inner 10% (close to the optic nerve) of the retina were again divided
into 10 parts and the thickness of the INL was measured.
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Figure 2.8: Example for a measurement on retinal thickness: For the measure-
ment each side of the retina was divided into 10 parts of equal length, and the
retinal thickness was measured for each part from the ganglion cell layer to the
apical side of the RPE (red lines). For the measurement the program Axiovision
from Zeiss was used.
2.4.5 Determination of axon number in optic nerves
To count the number of axons, mice that were treated with an NMDA injection
(see section 2.4.6) in one eye and PBS in the partner eye at the age of 6 weeks were
used. Three weeks after the injection the mice were killed, the optic nerves were
embedded in epon, see section 2.4.2, and cross sections 1 µm in thickness were
made. The sections were stained with a paraphenyldiamin staining, see section
2.4.3. Afterwards microscopic images with 100 x magnification were used to count
all axons of each nerve.
2.4.6 Intravitreal injection - the NMDA lesion model
The NMDA (N-methyl-D-aspartate) lesion is a method to damage retinal ganglion
cells and cells of the inner nuclear layer. NMDA is a glutamate analogon and as
such a synthetic agonist of the NMDA receptor, which is a ligand gated Ca2+
channel. In the model of exitotoxic damage, excess glutamate or NMDA binds to
the NMDA receptor, triggering calcium influx, organelle stress and activation of
pro-apoptotic pathways [136].
Prior to the intravitreal injection the animals were anesthetized with isoflurane.
For the injection a 33 gauge (G) needle attached to a Hamilton pipet was used.
NMDA (3 µl 10 mM) or PBS (3 µl) as a control substance were injected into the
vitreous body, through the sklera shortly behind the cornea, in the area of the
ora serrata. After removing the needle the eyes were treated with an antiseptic
substance (isomax-AS).
2.4.7 TUNEL staining
The TUNEL assay - a method to quantify apoptotic cell death The TUNEL method
(TdT mediated dUTP-biotin nick end labeling) is a method to label apoptotic
cells. The DeadEnd Fluorometric TUNEL system marks the fragmented DNA of
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apoptotic cells by incorporating fluorescein-12-dUTP at 3´-OH ends. This is done
by the enzyme Terminal Deoxynucleotidyl Transferase. During the experiment the
tissue was permeabilized by Triton or Proteinase K and incubated with an mix of
the enzyme and fluorescently labeled dUTP. The fluorescent cells can be evaluated
and counted directly by fluorescence microscopy [137].
TUNEL - protocol for cryo sections
• Rinse slides three times with phosphate buffer see 2.19, 5 minutes each time
• Immerse slides in 4 % formaldehyde for 25 minutes at 4◦C
• Immerse slides in 0.2 % Triton X-100 in phosphate buffer for 5 minutes
• Equilibrate slides with equilibration buffer (from the kit) at room tempera-
ture for 5-10 minutes
• Add TdT reaction mix to the slides. Incubate slides for 60 minutes at 37 ◦C
in a humidified chamber; avoid exposure to light from this step forward
• Immerse slides in 2X SSC for 15 minutes
• Immerse slides three times in phosphate buffer, 5 minutes each time
• Mount slides with mounting medium containing dapi
• Detect localized green fluorescence of apoptotic tissue by fluorescence mi-
croscopy
Protocol for paraffin sections
• Dewax and rehydrate the slides ignoring the H2O dest. step at the end; see
2.4.2 (Dewaxing and rehydration)
• Immerse slides in 50% isopropanol for 5 minutes
• Immerse slides in H2O dest. for 5 minutes
• Immerse slides in 0.85% NaCl for 5 minutes.
• Rinse slides three times with phosphate buffer, 5 minutes each time
• Immerse slides in 4 % formaldehyde for 15 minutes at 4◦C
• Rinse slides three times with phosphate buffer, 5 minutes each time
• Add 100 µl of a 20 µg/ml Proteinase K solution. Incubate at room temper-
ature for 8-10 minutes.
• Immerse slides in phosphate buffer for 5 minutes
• Immerse slides in 4 % formaldehyde in PBS for 5 minutes
• Immerse slides in phosphate buffer for 5 minutes
• Equilibrate slides with equilibration buffer at room temperature for 5-10
minutes
• Add TdT reaction mix to the slides. Incubate slides for 60 minutes at 37 ◦C
in a humidified chamber; avoid exposure to light from this step forward
• Immerse slides in 2X SSC for 15 min
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• Immerse slides three times in phosphate buffer, 5 minutes each time
• Mount slides with mounting medium containing dapi
• Detect localized green fluorescence of apoptotic tissue by fluorescence mi-
croscopy
TUNEL - staining in newborn Smad7fl/− mice The apoptosis rate in young Smad7fl/−
animals and their wildtype littermates was determined by carrying out a TUNEL
assay on 8 day old mice. The enucleated eyes were embedded in paraffin for a
better tissue preservation. After the TUNEL staining, the samples were evaluated
with fluorescence microscopy and the TUNEL positive cell were counted on both
sides of the optic nerve for every eye and averaged for the analysis.
TUNEL - staining after NMDA injection in Smad7- and TGF-β RIIfl/− mice Addi-
tionally to the axon count after NMDA injection, TUNEL stainings were made
to show the effect of the genetic alterations on the apoptosis after a lesion. For
the TUNEL assay 6 week old mice were killed 24 hours after the NMDA injec-
tion and the eyes were cryoembedded. For the staining the protocol for TUNEL
assays with cryo sections was used, see section 2.4.7. After evaluation under the
fluorescence microscope the cells in both halves of the retina were counted and
averaged for each eye.
2.4.8 BRDU assays and stainings - methods to quantify cell
proliferation
Injection of BRDU for in vivo experiments
Bromodesoxyuridine (BRDU) is a synthetic nucleoside analogon of thymidin. It is
widely used to mark proliferating cells in vivo and in vitro. During the S phase of
the cell cycle, cells incorporate the nucleotide analogon into the newly synthesized
DNA. Special antibodies are used to detect the nucleoside within the nucleus and
mark cells that proliferated since the injection of BRDU.
For in vivo experiments BRDU was injected intraperitoneally with a 34 gauche
needle in a concentration of 10 mg/ml in PBS for adult animals and a concen-
tration of 2 mg/ml for young mice. Prior to the injection the mice were weighed
and 50mg BRDU per kilogram bodyweight was used. The mice were killed at
different time points after the injection. The eyes were used for cryo- or paraffin
embedding, see section 2.4.2.
BRDU staining for paraffin sections
This is the BRDU protocol for paraffin sections. To apply it for cryo sections,
the first three steps have to be skipped. The protocol starts in this case from the
washing step before the incubation with 1 M HCl (step 4).
• Immerse slides in aqua dest.
• Immerse slides in 0.05 M Tris HCl for 5 minutes
• Incubate slides with proteinase K (100 µl in 47 ml 0.05 M Tris HCl) for 5
minutes
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• Rinse slides with aqua dest.
• Incubate slides in 1 M HCl for 30 minutes
• Rinse slides with aqua dest.
• Wash slides two times in 0.1 M phosphate buffer; 5 minutes each time
• Incubate slides in 5 % skimmed milk powder in 0.1 M Php for 45 minutes
• Incubate slides with 1:50 BRDU antibody (Invitrogen) in 0.5 % skimmed
milk powder over night at 4◦C
• Wash slides three times in 0.1 M phosphate buffer; 5 minutes each time
• Incubate slides with anti-mouse Biotin 1:500 for 1 h
• Wash slides three times in 0.1 M phosphate buffer; 5 minutes each time
• Incubate slides with Streptavidin Alexa 488 1:1000 for 1 h
• Wash slides three times in 0.1 M phosphate buffer; 5 minutes each time
• Mount slides with mounting medium containing dapi
BRDU staining in newborn Smad7fl/− mice The BRDU staining was used to eval-
uate the amount of proliferation in 4 day old Smad7fl/− mice compared to their
littermates. For this experiment the mice were injected with BRDU at P3 and
killed 24 hours later. Their eyes were enucleated and embedded in paraffin; see
section 2.4.2. After sectioning the protocol for BRDU staining in paraffin sections
was applied.
BRDU staining after NMDA injection in Smad7- and TGF-β RIIfl/− mice To show
the effect of an NMDA treatment on proliferation, BRDU was injected intraperi-
toneally right after the intraocular NMDA/PBS injection, see section 2.4.6. 24
hours later the BRDU injection was repeated. Again 48 hours after the first injec-
tion the mice were killed and their eyes were cryoembedded, sectioned and stained
for BRDU. Furthermore for the TGF-β RIIfl/− mice the experiment was repeated
by killing the mice 24 h after the first injection.
2.4.9 Apoptosis assays (TUNEL) and proliferation assays (BRDU)
in newborn mice
To choose the appropriate point in development for proliferation and apoptosis
studies in newborn mice the papers from R.W. Young were used [44,138]. Figure
2.9 shows that the maximum of the ontogenetic cell death of Mu¨ller is glia lies
about day 8. This time point was chosen for the TUNEL assays in newborn mice.
The proliferation maximum of the central retina is at day 3 that of the peripheral
retina at day 5, because of that day 4 was chosen for the proliferation studies.
2.4.10 LacZ staining of EIIa Cre x Rosa LacZ
To see where exactly the EIIa Cre recombinase is expressed in the retina, EIIa
Cre mice were crossed with Rosa LacZ reporter mice. When the Cre recombinase
is expressed in the same cell as the Rosa LacZ construct, a recombination in the
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Figure 2.9: Mu¨ller glia proliferation and cell death in newborn mice: The graph
with the solid circles shows all dead cells per 0.5 µm section from the optic nerve
to the ora serrata; The curve for the proliferation for the retinal center shows all
3H-thymidine labeled cells within 500 µm from the optic nerve; The proliferation
curve for the periphery shows all 3H thymidine labeled Mu¨ller glia cells within
500 µm from the ora serrata [44,138]. The maximum of ontogenetic cell death for
mu¨ller glia lies at P8, the maximum of proliferation between P3 and P5.
LacZ construct takes place causing the expression of β-Galactosidase in this cell.
During a staining this enzyme cleaves the artificial substrate x-gal. This results
in a blue color in the cell that carries the Cre recombinase. For the experiment 3
week old mice carrying the LacZ gene and the Cre recombinase were used. As a
negative control mice free of the Cre recombinase but carrying the LacZ construct
were chosen.
For the LacZ staining the eyes were enucleated and fixed for 30 min in LacZ
fixation solution; see Table 2.22. Subsequently the eyes were washed 3 times
for 15 min with LacZ washing buffer, see Table 2.23, followed by an over night
incubation in LacZ staining solution, see Table 2.24. The following day the eyes
were washed again 3 times for 15 min in LacZ washing buffer and were incubated
for at least 10 min in Php prior to further handling. The LacZ stained eyes were
treated with sucrose solutions following the protocol for paraffin embedding and
sectioning shown in section 2.4.2.
2.4.11 Immunostaining of tissue
For immunostaining paraffin sections and cryo sections were used. Paraffin sec-
tions had to be dewaxed and rehydrated prior to staining as shown in section 2.4.2
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LacZ fixation buffer
glutaraldehyde 25% 0.4 ml
EGTA 250 mM pH 7.3 1 ml
MgCl2 1 M 5 ml
sodium phosphate buffer (Php); pH 7.3; 0.1 M 43.5 ml
Table 2.22: LacZ fixation buffer.
LacZ washing buffer
MgCl2 1 M 1 ml
1% sodium desoxycholate 5 ml
2% tergitol 5 ml
phosphate buffer; pH 7.3; 0.1 M 489 ml
Table 2.23: LacZ washing buffer.
lacZ staining solution
lacZ washing buffer 72 ml
X-Gal (25mg/ml in DMSO) 3 ml
K4Fe(CN)6 x 3 H2O 0.159 g
K3Fe(CN)6 0.123 g
Table 2.24: LacZ staining solution.
and incubated in phosphate buffer prior to use. Cryo sections were washed 3 times
for 5 minutes in phosphate buffer (Php) (see Table 2.19) to wash off the tissue
tech. For blocking 3% BSA with 0.1% triton was used. The blocking solution was
applied on the tissue and the slides were incubated for 1 h at room temperature.
After 3 washing steps with Php the primary antibody see Table 2.25 was applied
and the slides were incubated over night at 4 ◦C. Subsequently the slides were
washed 3 times in phosphate buffer and the secondary antibody, see Table 2.26
was applied fo 1 h at room temperature. After three final washing steps with
phosphate buffer the slides were mounted with mounting medium containing 1:10
dapi for a nuclear staining and stored at 4◦C in the dark until use.
Primary
Dilution Source Buffer Company
antibody
Nestin 1:150 mouse 0.3% BSA 0.01% Triton BD Pharmingen
Glutamine 1:500 rabbit 0.3% BSA 0.01% Triton Sigma
synthetase
GFAP 1:300 rabbit 0.3% BSA .01% Triton Dako
Table 2.25: Primary antibodies for immunostaining.
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Secondary/Tertiary antibody Dilution Company
goat anti mouse alexa 488 1:2000 Invitrogen
goat anti rabbit alexa 488 1:1000 Invitrogen
goat anti rabbit alexa 546 1:1000 Invitrogen
Biotinylated anti mouse 1:500 Vector
Biotinylated anti rabbit 1:500 Vector
Streptavidin Alexa 488 1:1000 Molecular probes
Streptavidin Alexa 555 1:1000 Molecular probes
Cy3 goat anti rabbit 1:1000 Jackson immuno research
Table 2.26: Secondary antibodies for immunostaining.
20µm
Figure 2.10: Example for intensity measurement.
2.4.12 Nestin and GFAP stainings
Nestin and GFAP staining as a control for Mu¨ller glia cell activation in untreated
mice To see if a deficiency of Smad7 or TGF-β RII has any effect on the Nestin
expression in untreated mice, 3 week old mice were used. The eyes were enucleated
and cryo-embedded. The staining was done according to the protocol shown in
section 2.4.11, using anti mouse or anti goat alexa 488 secondary antibodies.
Nestin and GFAP staining as a control for Mu¨ller glia cells activation after NMDA
treatment After NMDA lesion, Mu¨ller cells are known to express more GFAP
and Nestin. To see if a deficiency of Smad7 or TGF-β RII alters or enhances
this reaction 6 week old mice were injected with NMDA. Three days after the
injection the mice were killed and their eyes were cryo-embedded. The sections
were stained with Nestin or GFAP according to section 2.4.11.
Measurement of Nestin fluorescence staining intensity with ZEN lite 2011 To deter-
mine the Nestin staining intensity in the Mu¨ller glia foot processes ZEN lite 2011
from Zeiss was used. To use a defined region for measurement the stained area
between the nuclei of the ganglion cell layer and the vitreous humor of the eye was
surrounded with a spline (red) as shown in Figure 2.10. The program calculates
the average intensity of the staining. This intensity is already normalized to the
area of the measurement.
2.4. HISTOLOGY AND IMMUNOHISTOCHEMISTRY 43
no nestin staining 
only tips of foot
processes stained
all footprocesses stained; 
staining reaches into INL
most parts of the 
footprocesses are stained
0
1
2
3
description scorestaining
Figure 2.11: Scoring for Nestin staining intensity.
Scoring of Nestin fluorescence staining intensity If it was not possible to use the
program ZEN to measure the staining intensity, for example due to background
staining, the stainings were examinated by eye and scored with the system shown
in Figures 2.11 and 2.12. To allow for further statistical analysis, the Mann-
Whitney test was used. To present these results graphically, box plots are used.
2.4.13 Glutamine synthetase staining (GS) - Evaluation of the
number of Mu¨ller glia cells in different mouse lines
For counting of the number of Mu¨ller glia cells in the retinae of the different
mouse lines, 3 week old mice were used. The mice were killed, the eyes enucleated
and cryo-embedded. Sagittal cryo sections through the papilla were stained with
glutamine synthetase, a marker for Mu¨ller glia as Figure 2.13 A shows. For this
staining the Biotin- Streptavidin system was used to get better results. Using the
Axio Vision 40† program from Zeiss, three 200 µm sectors of the retina on each
side of the optic nerve were determined: The first near the ora serrata (peripheral;
1), the second half way in between the ora serrata and the optic nerve (medial; 2)
and the third close to the optic nerve (central; 3) as shown in Figure 2.13 B. The
number of cellular bodies were determined, and for each eye the central, medial
and peripheral counts of the the two sides were averaged.
2.4.14 Light- and fluorescence microscopy
The analysis of the paraffin-, cryo- and epon sections was done with the help of a
Axio Imager Z1-microscope (Carl Zeiss, Go¨ttingen).
†Release 4.8.2.0
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Figure 2.13: (A) Staining of Mu¨ller glia with glutamine synthetase. (B) Count-
ing scheme.
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2.5 Quantification of mRNA expression
Quantitative real-time (RT)-PCR is a method to determine the amount of a cer-
tain messenger ribonucleic acid (mRNA) present in a sample by monitoring the
amplification process in real-time. For this method the mRNA has to be isolated
and transcribed into complementary DNA (cDNA).
2.5.1 Retina preparation for mRNA isolation
To isolate the retinae, mice were killed, their eyes were enucleated and a circular
cut was performed along the ora serrata to open the eye and remove the lens. The
retina was brushed out of the remaining rear part of the eyeball with a pair of
tweezers. The retinae of both eyes were pooled and immediately put into 200 µl of
peqGOLD TriFastTM. This fluid is a one phase solution of phenol and guanidine
isothiocyanate that lyses the cells, inactivates RNAses and stabilizes the RNA.
Subsequently the retinae in the Trizol were crushed with a pestle and either frozen
at -20 ◦C until RNA isolation or immediately processed.
2.5.2 RNA isolation with TriFastTM
To isolate the RNA from the tissue the method by Chomczynski and Sacchi
[139] was used. For this Chloroform was added to the lysed tissue and vortexed.
Through centrifugation the mixture separated into three phases and the RNA
could be precipitated from the upper aqueous phase with isopropanol. The exact
protocol is shown below.
• Add Chloroform (1/4 of the sample volume) to the lysed tissue and vortex
• Incubate 2-3 minutes at room temperature
• Centrifuge 20 min at 4 ◦C at 12.000 x g
• Transfer the upper aqueous phase to a new cup
• Add isopropanol (1/1 of the sample volume) to the upper phase and vortex
• Freeze over night at -20 ◦C
• Centrifuge 20 min at 4 ◦C at 12.000 x g
• Remove supernatant
• Add 700 µl 75 % ethanol
• Centrifuge 5 min at 4 ◦C at 7.500 x g
• Let the pellet dry
• Add 10 µl RNAse free H20
RNA can be stored at -80 ◦C.
2.5.3 RNA-quantification
The RNA concentration was determined measuring the UV absorption in a NanoDrop-
1000 Spectrometer. Using the optical density (OD) of the sample at 260 nm, the
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Reaction mix sample control
RNA 0.5 µg 0.5 µg
5x iScriptTM reaction Mix 2 µl 2 µl
iScriptTM reverse transcriptase 0.5 µl -
H20 fill to 10 µl fill to 10 µl
Table 2.27: Reaction mixture for cDNA synthesis.
temperature duration
25 ◦C 5 min
42 ◦C 30 min
85 ◦C 5 min
10 ◦C ∞
Table 2.28: Cycler program for cDNA synthesis.
absorption peak of nucleic acids, the RNA concentration was calculated as equa-
tion 2.1 shows.
RNA concentration [µg/ml] = OD260 · 40 µg/ml (2.1)
The purity of the RNA was determined by the the OD260/OD280 ratio, where
the OD280 is proportional to the the concentration of proteins in the sample. A
ratio between 1.8 and 2.0 indicates pure RNA.
2.5.4 cDNA synthesis
To perform a quantitative real-time (RT)-PCR, a stable form of the extracted
mRNA was needed. To achieve this, cDNA (copy DNA or complementary DNA)
was synthesized in vitro from the mRNA template using the enzyme reverse tran-
scriptase. Due to the use of oligo dT primers only the poly A tailed mRNA is
transcribed in this method. To exclude that any signal in the real-time PCR
originated from cDNA as template and not from DNA, a negative control with-
out the reverse transcriptase (-RT control) was prepared in this step. For the
reaction the ”iScript cDNA Synthesis kit” by Biorad was used. The composition
of the reaction mixture is shown in Table 2.27. The reaction was performed in a
thermocycler using the program shown in Table 2.28
The synthesis of the cDNA takes place during the 42◦C step the reverse tran-
scriptase is inactivated at 85◦C. The cDNA was stored at -20◦C until use. By
determining the amount of a certain cDNA in the sample the amount of the
corresponding mRNA can be evaluated.
2.5.5 Quantitative real-time (RT)-PCR
All real-time analysis were carried out with the RNA (transcribed to cDNA) of
the retinae of three week old mice. To get enough RNA, the retinae of the two
eyes per mouse were pooled.
The quantitative real-time RT-PCR is a method to determine the concentration
of a certain mRNA/cDNA in a sample [140]. During RT-PCR an amplification re-
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name sequence
GNB2L1 fw 5’gctactaccccgcagttcc3’
GNB2L1 rev 5’cagtttccacatgatgatggtc 3’
(Guanidine nucleotide binding protein 2 like 1)
mSmad7 RT fw 5’cccaatggattttctcaaacc 3’
mSmad7 RT rev 5’gggccagataattcgttcc 3’
(Mothers Against Decapentaplegic homolog 7)
m TGFbr2 Ex2 fw 5’agaagccgcatgaagtctg 3’
m TGFbr2 Ex3 rev 5’ggcaaaccgtctccagagta 3’
(Transforming growth factor receptor II)
Nestin fw 5’ctgcaggccactgaaaagtt 3’
Nestin rev 5’tctgactctgtagaccctgcttc 3’
CTGF fw 5’tgacctggaggaaaacattaaga 3’
CTGF rev 5’agccctgtatgtcttcacactg 3’
(Connective tissue growth factor)
Table 2.29: Q-PCR primers.
Reaction mix
cDNA 0.15 µl
10x PCR-buffer 1.5 µl
MgCl2(25 mM) 0.6 µl
dNTPs (25 mM) 0.12 µl
Sybr-Green I 0.19 µl
Fluorescein 0.015 µl
Taq DNA polymerase (5U/µl) 0.06 µl
H20 7.37 µl
Primer mix 5 µl
Primer mix
H20 60.5 µl
Primer forward (1 µM) 1 µl
Primer reverse (1 µM) 1 µl
Table 2.30: Reaction mixture for real-time PCR.
action is performed and the amount of the PCR product is continuously measured
during the reaction.
For the amplification reaction the master mix and the Taq polymerase of the
HotStart Taq Kit (Quiagen) were used. The reaction mix was prepared as shown
in Table 2.30. The primers (see Table 2.29) were constructed by using the Uni-
versal probe library‡ and ordered from Invitrogen.
As cycler a iQ5 Multicolor Real time-PCR Detection System iCycler was used.
Table 2.31 shows the standard cycler program. The reaction was carried out in 96-
well-format plates with every sample measured as triplicate and for every sample
a -RT control as described in sec. 2.5.4.
‡www.roche-applied-science.com
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step temperature duration
step 1 (1x) 95 ◦C 15 min
step 2 (40x) 95 ◦C 10 s
60 ◦C 40 s
step 3 (1x) 95 ◦C 1 min
step 4 (1x) 55 ◦C 1 min
step 5 (81x) 55 ◦C 6 s
melting curve + 0.5 ◦C per cycle
Table 2.31: Cycler program for quantitative RT-PCR.
To track the amplification in real-time, the fluorescent dye SYBR green is in-
corporated into the DNA and fluoresces strongly when the DNA is in double
stranded conformation. The fluorescence is excited by a laser and the amount of
fluorescence is equivalent to the amount of PCR product present in the sample.
Knowing the cycle when the fluorescence PCR product reaches a defined concen-
tration threshold lying in the exponential phase of the amplification(CT ; cycle
threshold), the original amount of mRNA in the sample can be calculated.
For the concentration of any amplified gene cgene(CT ) versus the cycle count CT
holds the following relation:
cgene(CT ) = cgene(0) · 2CT (2.2)
In the used method, the amount of fluorescence was not directly calibrated to a
certain cDNA concentration. Because of this, the CT value of the gene of interest
had to be compared to the CT value of a housekeeping gene that is not affected
by the treatment or genetic modification. In this way the relation between the
housekeeper gene and the gene of interest could be calculated. With this form
of normalization the mRNA amount of the gene of interest in different samples
could be compared.
Assuming the concentration of the housekeeping gene passes the threshold at
cycle CT,hk, while the concentration of the amplified gene of interest does so at
cycle CT,g, the ratio of the starting concentrations is
cg(0)
chk(0)
= 2CT,hk−CT,g (2.3)
with chk being the concentration of the housekeeper cDNA and cg the con-
centration of the gene of interest cDNA. To exclude a signal that is caused by
unspecific products like primer-dimers a melting curve was produced at the end
of the amplification. The data was evaluated with the iCycler IQ Optical System
software.
2.6 Protein biochemical techniques
2.6.1 Protein isolation with the trizol method
For protein isolation the organic phase from the phenol-chloroform extraction of
the RNA was used, see 2.5.2. All samples used for western blots were taken from
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washing buffer
guanidine HCl 0.3 M
solve in 95 % ethanol
Table 2.32: Washing buffer for protein isolation.
the retinae of three week old mice. To isolate the proteins from the organic phase
following protocol was used.
• Add 900 µl isopropanol to the remaining phenol-chloroform phase
• Incubate for 10 min at room temperature
• Centrifuge for 10 min at 16.000 x g
• Remove supernatant
• Wash pellet with washing buffer (see Table 2.32) for 3 times and with 95%
ethanol the fourth time; centrifuge after each washing step 5 min at 4 ◦C
and 7500 x g
• Add about 150-200 µl of 1% SDS with protease inhibitor 1:1000 and phos-
phatase inhibitor 1:100
• Incubate at 50 ◦C over night
• Centrifuge 10 min at 10000 x g and use supernatant
2.6.2 Sodium-dodecyl-sulfate polyacryl-amid gel electrophore-
sis: SDS PAGE
To separate the proteins according to their size the method of discontinuous SDS
page by Laemmli [141] was used. In this method the proteins are completely
denaturated and brought to a negative charge proportional to their size by binding
SDS to their hydrophobic regions. The separation of the proteins is done by gel
electrophoresis. Due to a two part gel- and buffer system, that is different in
pH, acrylamide- and ion concentration, the proteins are focused in a stacking gel
between the leading Cl- ions and the following Glycine- ions and resolved by their
size in the resolving gel. Table 2.33 shows the gel composition of both components
and Table 2.34 the buffer needed to pour and run the gel. According to the protein
size a different acrylamide concentration of the resolving gel can be chosen.
To pour the gels, the vertical gel casting system by PeqLab Biotechnology
GmbH was used. The casting chamber was set up according to protocol. To
cast the gel, the resolving gel solution was filled between the two glass plates and
overlayed with isopropanol. After polymerization the isopropanol was removed,
the stacking gel solution was poured between the glass plates. A comb was inserted
into the fluid stacking-gel to form the gel pockets. When the stacking gel is solid
the gel casting device was inserted into the electrophoresis chamber according to
protocol. The comb was removed and the chamber was filled with electrophoresis
buffer. Prior to loading 15 µl of protein were mixed with 4x Laemmli buffer, see
Table 2.34 and heated for 5 min to 100 ◦C in a water bath to denaturate the
protein. To run the gel 5 µl of marker (PageRulerTM Prestained Protein Ladder;
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Gels for SDS-PAGE Stacking gel Resolving gel 10 %
(1 ml) (5 ml)
H2O dest. 0.68 ml 1.9 ml
Rotiphorese R© Gel 30 0.17 ml 1.7 ml
Tris/HCl, 1 M, pH 6.8 0.13 ml -
Tris/HCl, 1.5 M, pH 8.8 - 1.3 ml
10 % SDS 0.01 ml 0.05 ml
10 % APS 0.01 ml 0.05 ml
TEMED 0.001 ml 0.002 ml
Table 2.33: Gel composition for SDS gel electrophoresis; Buffers are shown in
Table 2.34.
Buffer Composition
SDS-solution, 10 % (w/v) 10 g SDS
solve in H2O dest. ad 100 ml
SDS-Laemmli buffer, 4x 0.25 M Tris/HCl, pH 6.8
30 % glycerin
8 % (w/v) SDS
0.02 % (w/v) bromophenol blue
10 % ß-mercaptoethanol
10 x SDS electrophoresis buffer 250 mM Tris/HCl
400 mM Glycine
1 % (w/v) SDS
solve in H2O dest. ad 1 l
Tris/HCl, 1.0 M, pH 6.8 121.14 g Tris
solve in H2O dest .ad 1 l
adjust pH
Tris/HCl, 1.5 M, pH 8.8 181.71 g Tris
solve in H2O dest .ad 1 l
adjust pH
Table 2.34: Buffers for SDS gel electrophoresis.
Fermentas) and all of the protein solution were loaded into the gel pockets and
the power supply was set to 45-60 min at 20 mA.
2.6.3 Western blot protein transfer
To transfer the separated proteins from the resolving gel to the Polyvinylfluo-
ride (PVDF)- membrane (Roche, Mannheim) a Semidry Blotting device (Peqlab
Biotechnology GmbH, Erlangen) was used. The PVDF membrane was cut to the
size of the resolving gel and incubated for 15 s in methanol to activate the surface.
Subsequently the membrane was washed for 1 minute in distilled water and equi-
librated for 5 minutes in transfer buffer. The whatman papers were equilibrated
in transfer buffer as well, see Table 2.35. The stacking of the blot was done as
shown in Table 2.36. Blotting was done for 1.5 h at 25 V.
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10x transfer-buffer
Tris 5.8 g
glycine 2.9 g
methanol 200 ml
SDS 3.7 ml 10 % (w/v)
solve in H2O dest., ad 1 l
Table 2.35: Transfer buffer for western blotting.
cathode (-)
3 layers whatman-paper
resolving gel
PVDF-membrane
2 layers whatman-paper
anode (+)
Table 2.36: Stacking scheme for western blotting.
TBS, 10x, pH 7.4
Tris/HCl 30 g
NaCl 80 g
KCl 2 g
fill with H2O dest. ad 1 l
TBST, 1x
10x TBS 100 ml
Tween 20 0.05 % (v/v)
fill with H2O dest. ad 1 l
Table 2.37: TBS and TBST buffer for immunostaining.
2.6.4 Western blot immunostaining
To detect the protein of interest on the PVDF membrane after blotting, an an-
tibody against the protein was used. To prevent the antibody from binding un-
specifically, the membrane was incubated in 5% BSA in TBST or 5% skimmed
milk (SM) powder in TBST (see Table 2.37) prior to the antibody treatment. Af-
ter blocking, the membrane was incubated in the primary antibody solution (see
Table 2.38) over night at 4◦C. For that, the antibody was solved in TBST with
10% blocking solution. After washing the membrane 3 times for 5 minutes with
TBST, the secondary antibody (see Table 2.39) was applied for 1 hour. This anti-
body carried horseradish peroxidase (HRP), an enzyme that can convert luminol
to a fluorescing product.
Prior to detection the membrane was again washed 3 times for 5 minutes with
TBST and 1 ml of HRP Substrate Luminol Reagent mixed with HRP Peroxidase
Solution (1:1) was applied. After 5 minutes incubation time the fluorescence
was detected by the LAS 3000 digital intelligent dark box and analyzed by Aida
Advanced Image Data Analyzer Version 4.06.
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Primary dilution source buffer company protein size
antibody (in TBST)
TGF-β RII 1:200 rabbit 0.5% SM Santa cruz 70 kDa
C16
pSmad3 1:200 rabbit 0.5% BSA Cell signaling 52 kDa
CTGF 1:5000 rabbit 0.5% BSA Gene Tex 38 kDa
pERK 1:500 rabbit 0.5% BSA Cell signaling 44.42 kDa
Akt 1:1000 rabbit 0.5% BSA Cell signaling 60 kDa
pAkt 1:500 mouse 0.5% BSA Cell signaling 60 kDa
GAPDH HRP 1:10.000 rabbit 0.5% BSA Santa Cruz 37 kDa
conjugate
Table 2.38: Primary antibodies; SM = skimmed milk powder, BSA = bovine
serum albumin.
Secondary antibody dilution company
chicken anti rabbit HRP 1:2000 Santa cruz
chicken anti mouse HRP 1:2000 Santa cruz
Table 2.39: Secondary antibodies.
Coomassie-staining
methanol 40 ml
acetic acid 2 ml
Coomassie-Brilliant Blue R250I 0.2 g
fill with H2O dest. ad 100 ml
Coomassie-destainer
Methanol 500 ml
acetic acid 1 ml
fill with H2O dest. ad 1 l
Table 2.40: Solutions for Coomassie staining and destaining.
2.6.5 Coomassie staining for loading control
The protein dye triphenylmethan Coomassie-brilliant blue R 250 is used to stain
proteins on the PVDF membrane unspecifically. It binds to basic sidechains of
proteins. To stain the membrane it was put into the staining solution, see Table
2.40, for 10 minutes. To remove the excess dye the membrane was incubated
in Coomassie destaining solution (see Table 2.40) over night. Subsequently the
membrane was dried.
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reagents, media and equipment company
BrdU Cell proliferation ELISA (colorimetric) Roche, Mannheim
Dulbecco’s modified eagle
PAA, Pasching, AT
medium (DMEM) 4500
ethanol, absolute Roth, Karlsruhe
fetal bovine serum Invitrogen, Karlsruhe
collagenase A Sigma, Taufkirchen
Gentamycin (5 mg/ml) Invitrogen, Karlsruhe
Penicillin-Streptomycin Invitrogen, Karlsruhe
phosphate buffered saline (PBS) Invitrogen, Karlsruhe
Trypsin/EDTA (0.05 %) Invitrogen, Karlsruhe
Sunrise-basic ELISA-Reader Tecan Austria, Grodig, AT
cell culture flasks, well plates Nunc, Roskilde, DK
Petri dishes Sarstedt, Nurnbrecht
Julabo SW20 water bath Julabo Labortechnik, Seelbach
Hera Cell 150 incubator Heraeus, Hanau
Hera Cell 150 clean bench Heraeus, Hanau
serological pipettes Sarstedt, Nurnbrecht
Table 2.41: Reagents, media and equipment for cell culture.
Mu¨ller cell medium
DMEM medium 500 ml
FCS (serum) 50 ml
penicillin streptamycin mixture 5 ml
gentamycin 1 ml
Table 2.42: Mu¨ller cell medium.
2.7 Cell culture
2.7.1 Cell culturing techniques
All cells were cultured and treated under sterile conditions. All single use items
were wrapped in sterile packaging, the glassware used was autoclaved. All me-
dia and buffer were sterile and mixed under the clean bench if necessary. Cell
cultivation was carried out in Hera Cell 150 incubators at 37 ◦C and 5 % CO2.
During culture the medium was changed every two to three days. For splitting,
the cells were washed with sterile PBS and treated with trypsin-ethylene- diamine-
tetraacetic- acid (EDTA) for about 2 min at 37 ◦C. The enzymatic reaction was
stopped with Mu¨ller glia medium, see Table 2.42 and the cell suspension was zen-
trifuged at 1000 rpm for 5 min. Depending on the experiment the cell were seeded
in different concentrations for treatment or further cultivation.
2.7.2 Cell counting with the CASY Cell Counter
To evaluate the number of cells per ml prior to seeding a CASY Cell Counter
and Analyzer TT was used. The cells were washed with PBS and detached from
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digestion solution
serum free Mu¨ller cell medium 2 ml
trypsin 500 µl
collagenase I 70 U/ml
Table 2.43: Mu¨ller cell digestion solution.
the flask using trypsin-EDTA. To stop the reaction Mu¨ller glia cell medium with
serum was used. Subsequently 50 µl of cell suspension were mixed with 10 ml of
sterile Casy-ton (from OLS) and used for the measurement.
2.7.3 Enrichment of rat Mu¨ller glia cells for cell culture
The enrichment of rat Mu¨ller glia cells was done by the method of Hicks and
Courtois [142]. To achieve an enriched culture, Wistar rats were killed between
P8 (postnatal day) and P12 and the eyes were enucleated. After piercing them
with a needle they were incubated in serum free Mu¨ller cell medium over night
at room temperature. To digest the cells the eyes were incubated for 20 min in
digestion solution, see Table 2.43, at 37 ◦C and digestion was stopped by removing
the solution and adding medium with serum. To isolate the retinae a circular cut
was performed along the ora serrata to open the eye and remove the lens. The
retina was brushed out of the remaining rear part of the eyeball with a pair of
tweezers and transferred to a 2 ml petri dish containing PBS solution on ice. For
one small flask the retinae of 8 to 10 eyes were needed. By pipetting up and down
with a 1 ml eppendorf pipette the retinae in the PBS solution were homogenized
and subsequently centrifuged at 1000 rpm for 5 min. The cell pellet was dissolved
in DMEM medium and seeded in small cell culture flasks containing 5 ml Mu¨ller
cell medium, see Table 2.42, flasks were incubated at 37◦C and not moved for
the following 3-4 days. When cells started to grow from the retina debris the cell
layer was washed by pipetting the overlaying medium on it and by changing the
medium afterwards. The remaining cells are considered as Mu¨ller glia to a high
percentage confirmed with stainings and expression analysis [143].
2.7.4 Colorimetric cell proliferation ELISA
The thymidin analogon bromodesoxyuridine is incorporated into the DNA during
the amplification of the DNA in cell proliferation. The more proliferation, the
more BRDU is incorporated into the cells. BRDU can be detected in cell culture
by an antibody carrying a Peroxidase (POD). This enzyme catalyzes the conver-
sion of the chromogen substrate 3,5,3,5-tetramethylbenzidine into a the chromatic
complex 3,5,3,5-tetramethylbenzidine semiquinone-imine. The reaction is stopped
by adding H2SO4. This also changes extinction of the molecule from 450 nm (blue)
to 690 nm (yellow). The extinction of each well caused by this reaction product
is proportional to the BRDU incorporated and to the proliferation in the well.
To test the effect of TGF-β 1 on the proliferation of rat Mu¨ller glia cells the
colorimetric cell Proliferation ELISA from Roche was used. Primary Mu¨ller glia
cells (P1; passage 1) were seeded in Mu¨ller cell medium with serum in a density of
2 · 104 cells per well using a 96 well plate (P2). Two wells were left without cells
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to act as a blanc. After the cells had settled they were washed with PBS, and
100 µl/well serum free Mu¨ller glia cell medium containing 1:1000 BRDU (10 µl
final concentration) labeling reagent was applied. In one third of the wells no
TGF-β 1 was added to the medium as a control. For another third 2 ng/ml
TGF-β 1 and for the last third 4 ng/ml TGF-β 1 were added. The well plates
were incubated for 24 h at 37 ◦C. After the treatment the supernatant medium
was tapped off and 200 µl of Fix denat solution were added to each well. After
30 minutes the solution was tapped of and the anti BRDU POD working solution
was applied and incubated for 90 minutes. After removing the antibody solution
by tapping, the plates were rinsed for three times with washing solution 200-
300 µl/well (PBS). For the detection substrate solution (100 µl/well) was applied
and after 5 minutes the reaction was stopped by adding 25 µl/well of 1M H2SO4.
The absorbance was measured with a Sunrise-Basic ELISA-Reader (Tecan) at
690 nm. After the measurement the average value of the blank wells (without
cells) was subtracted from all measured values.
2.7.5 TGF-β 1 treatment and RNA isolation from Mu¨ller glia
cells
For RNA isolation P0 primary Mu¨ller glia grown from the seeded retinae, were
split from a small 5 ml flask to two 6 well plates for treatment. As soon as the cell
layer was about 80 % dense the cells were washed with sterile PBS and 3 of the
wells of each plate were treated with serum free Mu¨ller cell medium containing
2 ng/ml TGF-β 1. Three of the wells served as a control and were treated with
serum free medium only. To harvest the cells 200 µl of trizol were added to each
of the wells and the 600 µl were used pooled for RNA isolation.
2.8 Diagrams and Statistics
In all diagrams beside the box plots values are shown as mean ± SEM. In box
plots used to show ordinal (score) data, the boundary of the box closest to zero
indicates the 25th percentile, a line within the box marks the median, and the
boundary of the box farthest from zero indicates the 75th percentile. Whiskers
(error bars) above and below the box indicate the 90th and 10th percentiles.
For the statistical analysis of numeric data the student T test, for ordinal data
(scores) the Mann - Whitney test was performed. A p-value < 0.05 was considered
significant and marked with an asterisk (*) in diagrams.

Chapter 3
Results
3.1 Aims and ideas
The aim of this work was to evaluate the effect of the TGF-β pathway on pre-
cursor cell populations in the mouse retina, especially on Mu¨ller glia cells. To
influence the TGF-β pathway, mainly two mouse models were used: One with a
heterozygous deletion of exon II of TGF-β RII (Transforming growth factor beta
receptor II), to investigate the effects of reduced TGF-β signaling; the other with
a heterozygous deletion of the promoter and exon I of Smad7, an inhibitor of the
TGF-β pathway, to study an increased TGF-β signaling. Additionally CTGF
overexpressing mice, as a target protein for the TGF-β pathway, and mice with
a Tamoxifen inducible TGF-β RII homozygous deletion in the retina were exam-
ined. With the help of these mouse models we evaluated if the TGF-β pathway
had any effect on proliferation, cell death, activation or the reaction of retinal
precursor cell populations to lesions.
3.2 Expression of EIIa Cre recombinase - EIIa mice
x Rosa LacZ
To create TGF-β RII or Smad7 deficient mice with the help of the Cre Lox
system, EIIa Cre mice were used for breeding. This mouse strain expresses a Cre
recombinase under the adenoviral EIIa promoter with an early ubiquitous onset.
To see in which retinal cells the EIIa Cre recombinase actually leads to a re-
combination, we bred EIIa Cre mice to Rosa LacZ mice. This reporter mice are
used to label regions where the Cre recombinase is active. In cells where the re-
combination occurs, β-Galactosidase is expressed and can be detected in sections
by β-Galactosidase staining.
Interestingly the Cre recombinase under the control of an EIIa Cre promoter
leads to a strong mosaicism in the first generation of breeding. Only some cells
carry the recombination in the very beginning, but as the recombination occurs
very early in the embryo, it is inherited to all cells that originate from this pro-
genitor. In the retina this leads to a stripe pattern, where supposeably so called
columnar units are stained (Figure 3.1 A). Columnar units are retinal units where
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Figure 3.1: Mosaicism of EIIa Cre recombinase expression after breeding with
EIIa Cre: (A) The LacZ staining shows regions with active Cre recombinase
where the recombination took place. It depicts a stripe pattern in the retina -
marked with an asterisk - that is possibly formed by so called columnar units.
(B) Schematic drawing of a columnar unit: The structures in the retina originate
from a single progenitor cell and are assembled as shown in the Semi-schematic
drawing (taken from [151]). ONL = outer nuclear layer, INL = inner nuclear
layer, GCL = ganglion cell layer.
cells originating from a single progenitor cell are arranged in a column like struc-
ture around one central Mu¨ller glia cell [144–151] (Figure 3.1 B). The feature of
marking related cells makes the EIIa Cre x Rosa LacZ mouse an interesting model
for clonal analysis of tissues.
For our purpose the mosaicsm was a problem, solved by the elimination of
the Cre recombinase during breeding and by establishing a stable heterozygous
inheritable deletion. The breeding of these mouse models is shortly described in
the following.
3.3 Effects of an altered TGF-β pathway
3.3.1 Breeding of Smad7fl/− and TGF-β RIIfl/− mice
To analyze the influence of an increased TGF-β signaling, Smad7fl/− mice were
used, as Smad7 is an inhibitor of the TGF-β pathway. It was not possible to work
with a homozygous mouse model in this case, because the homozygous deletion
proved to be lethal at a late embryonic stage.
By crossing EIIa Cre animals with the Smad7fl/fl mice, recombination and
deletion of the exon I of Smad7 occurred. This deletion could be detected by the
deletion PCR established by Ingo Kleiter [131], see section 2.3.6. During breeding,
the genetic status was confirmed by performing PCRs for EIIa Cre recombinase
and for the flox sequences. After the initial phase of breeding, the animals did
not carry the EIIa Cre recombinase anymore, but inherited the heterozygously
deleted sequence. Littermates without the deletion of Smad7 but homozygous for
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floxsites (Smad7fl/fl) served as a control. Additionally TGF-β RIIfl/− mice were
used as a model for reduced TGF-β signaling. To create a mouse line, comparable
to the Smad7fl/− mice, the breeding was done analogously to that of the Smad7
mice. For the exact breeding procedure, see section 2.2.10. The procedure for
genotyping can be found in section 2.3.6.
3.3.2 Confirmation of gene deletion and gene product defi-
ciency
Confirmation of the heterozygous deletion in Smad7fl/− mice
First, it had to be confirmed that the applied breeding procedure (section 2.2.10),
lead to a ubiquitous heterozygous deletion on DNA level in the Smad7fl/− mice.
To show that the recombination had occurred, a Smad7 deletion PCR [131] was
performed for mouse tail DNA and for retina DNA.
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Figure 3.2: Confirmation of gene deletion and RNA deficiency in Smad7fl/−
mice: (A) Scheme of Smad7 deletion PCR: Only DNA with a deletion of exon I
results in a product in PCR. (B) Gel picture of deletion PCR: Smad7fl/− mice
show deletion in mouse tail and retina DNA (n = 3/2 (wt/het)). (C) Smad7
expression on RNA level in retinae of Smad7fl/− mice and their wildtype litter-
mates: The Smad7 level in the Smad7fl/− mice is reduced significantly to about
40% of the wildtype level (n = 6; p = 0.044).
The PCR only generates a product when the recombination took place, be-
cause the product for the non recombined DNA is too long for amplification
(Figure 3.2 A). In a gel picture (Figure 3.2 B) bands can be seen for the retina
and mouse-tail of the Smad7fl/− animal, but not for its wildtype littermate (n =
3/2 (wt/het)).
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Confirmation of the Smad7 deficiency on mRNA level
After demonstrating the deletion on DNA level, the deficiency of Smad7 on mRNA
level had to be confirmed. Quantitative real-time PCR was used to test RNA
samples from retinae of Smad7fl/− mice and their wildtype littermates for their
Smad7 mRNA levels (n = 6). Figure 3.2 C shows the normalized Smad7 ex-
pression in heterozygous Smad7-deficient mice and their wildtype littermates. In
heterozygous Smad7-deficient mice, the Smad7 expression is significantly reduced
to about 40% of the level observed in wildtype mice. This is in good agreement
with the expected level after a mouse with a heterozygous gen deletion.
Confirmation of the TGF-β RII deletion on DNA and deficiency on protein
level
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Figure 3.3: (A) TGF-β RII fl/− mice carry the deletion in the retina: The
DNA gel shows a positive reaction of the deletion PCR for the retina DNA of
all heterozygous mice (n= 2/5 (wt/het)). (B) The TGF-β RII protein level is
reduced markedly in TGF-β RIIfl/− mice: The western blot was done with the
retina protein of 3 week old mice (n=4/5). (C) In real-time data a trend to a
decreased TGF-β RII level can be seen (n=6).
For the TGF-β RII mice the confirmation of the recombination on DNA level
was done analogously to the Smad7 mice. The deletion PCR, also used for geno-
typing the animals, was performed with retina DNA of 3 week old genotyped mice.
Like the deletion PCR used for the Smad7 mice, this PCR only shows bands if the
target gene is deleted. All animals positive for the heterozygous deletion in the
tail DNA were also positive for the deletion in the retina, whereas the wildtype
animals did not carry the deletion (Figure 3.3 A).
Additionally to the deletion on DNA level a TGF beta RII deficiency could be
shown on protein level. Western blot analysis for TGF-β RII, done with retina
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protein of 3 week old mice, showed that the level of protein in the heterozygous
animals was markedly lower than in wildtype mice (Figure 3.3 B). In Figure 3.3 C
real-time data of the TGF-β RII mRNA level in the retinae of TGF-β RII fl/−
mice and their wildtype littermates is shown. In this case a trend to a decreased
mRNA level in TGF-β RII fl/− mice can be seen.
3.3.3 Phenotype analysis
Histological phenotype of Smad7fl/− mice
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Figure 3.4: Phenotype analysis in 3 week old Smad7fl/− mice: The eyes of
heterozygous Smad7-deficient mice (A) show no apparent morphological differ-
ences compared to their wildtype littermates (B). Micrographs in higher mag-
nification (C), taken close to the optic nerve head, show no difference in the
organization and structure of the retinal layers. GCL = ganglion cell layer, INL
= inner nuclear layer, ONL = outer nuclear layer, ONH = optic nerve head.
To evaluate any morphological changes in the retina, eyes of 3 week old Smad7fl/−
mice and their wildtype littermates were enucleated and embedded in epon. Sagit-
tal semithin sections through the papilla, 1 µm in thickness, were stained with
Richardson’s stain and evaluated by light microscopy. Figure 3.4 shows light mi-
crographs of the eye of a heterozygous Smad7-deficient mouse (A) and its wildtype
littermate (B). Higher magnifications are shown in C.
The structure of the eye of the Smad7-deficient mouse and the retinal cell layers
appear to be regular defined. No apparent changes in retinal thickness are visible.
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The size of the eyes is normal and the higher magnifications show no difference
in the organization and structure of the retinal layers. Nevertheless, through
detailed measurements distinct morphological changes in the central retina can
be detected, as will be shown in section 3.3.4.
Phenotyping TGF-β RIIfl/− mice
Analogous to the Smad7 mice, epon sections of 3 week old mice were examined.
Figure 3.5 shows micrographs of TGF-β RII fl/− mice (A) and their wildtype
littermates (B). Comparing the eyes of TGF-β RIIfl/− and wildtype mice, no
phenotypic changes were found. The size of the eye and the thickness of the retina
remained unchanged. Higher magnifications showed no changes in the different
layers of the retina as well (Fig. 3.5 C).
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Figure 3.5: Micrographs of 3 week old TGF-β RII fl/− mice (A) and their
wildtype littermates (B). The structure of both eyes appears to be regular. No
morphological changes could be found. Neither were changes detected in the
structure of the retinal layers (C). GCL = ganglion cell layer, INL = inner nuclear
layer, ONL = outer nuclear layer, ONH = optic nerve head.
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3.3.4 Measurements of retina thickness
Increased retinal thickness in Smad7fl/− mice
As we were interested in any changes in proliferation or cell death, thickness
measurements of the retinae of 3 week old mice were conducted. For the measure-
ments, the epon semithin sections referred to in section 3.3.3 were used. Looking
at the retina thickness of Smad7fl/− mice, morphological changes in the cen-
tral retina can be seen. As figure 3.6 shows, the inner 10% of the retina of the
Smad7fl/− are thickened significantly compared to their wildtype littermates. The
change in thickness amounts to about 10 µm, which is about 5% of the thickness
of the whole retina.
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Figure 3.6: Measurement of retina thickness in Smad7fl/− mice: Next to the
Optic nerve head (ONH) the retina of the Smad7fl/− mice is thickened significantly
compared to their wildtype littermates (n=5/7 (wt/het), p ≈ 0.03). The change
in thickness amounts to about 5% of the thickness of the whole retina. ONH =
optic nerve head; OS = ora serrata.
Increased thickness of inner and outer nuclear layer in Smad7fl/− mice
Figure 3.7 shows a compilation of pictures from the optic nerve head of 3 week
old Smad7fl/− mice and their wildtype littermates. For a better visualization, the
inner nuclear layer was colored digitally. Taking a closer look, the inner nuclear
layer and the outer nuclear layer appear to be thickened. The measurement of
the outer nuclear layer, and the inner 10% of the inner nuclear layer reveals that
both layers are slightly, but nevertheless significantly thickened around the optic
nerve head (Figure 3.8). The change in thickness amounts to up to 20% for the
and inner nuclear layer and up to 10% for the outer nuclear layer of smad7 the
deficient mice compared to their littermates.
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Figure 3.7: Micrographs taken at the optic nerve: Inner and outer nuclear layer
of the Smad7fl/− mice appear to be thickened where they reach the optic nerve
head, marked by an asterisk (*) in the first row. For a better visualization the
inner nuclear layer was colored digitally.
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Figure 3.8: Measurement of the inner and outer nuclear layer thickness in
Smad7fl/− mice: (A) Thickness of the inner 10% of the inner nuclear layer is
increased significantly: In the inner 10% of the retina, an up to 20% thickening
of the inner nuclear layer is visible (n= 5/5, p = 0.042/0.023).
(B) Thickness of the outer nuclear layer is increased significantly: Close to the
optic nerve head, the outer nuclear layer is about 10% thicker than in the wildtype
littermates (n = 5/6 (wt/het), p = 0.03).
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Figure 3.9: (A) Measurement of the retina thickness of TGF-β RII fl/− mice:
No change in the thickness of the retina could be found comparing TGF-β RII fl/−
mice and their wildtype littermates (n = 5). (B) Retina thickness of Tamoxifen
induced CAG Cre x TGF-β RII fl/fl mice and their wildtype littermates: It is
noteworthy that the average retina thickness of the mice with the conditional
homozygous deletion of TGF-β RII is significantly smaller than in the wildtype
mice, which is the contrary effect to the Smad7-deficient mice (n = 5/6 (wt/kn),
p=0.047). OS = ora serrata; ONH = optic nerve head.
Influence of TGF-β RII heterzygous deletion and conditional homozygous
deletion on retina thickness
To see if the heterozygous deletion of TGF-β RII has a contrary effect on the retina
thickness compared to the Smad7-deficient mice, measurements on both sides of
the optic nerve were conducted and averaged for every eye. The TGF-β RII fl/−
mice showed no change in retina thickness compared to their wildtype littermates.
Even close to the optic nerve, where the heterozygous deletion of Smad7 showed
an effect on the retina thickness, no differences could be seen (Figure 3.9 A). It is
noteworthy that an induceable homozygous deletion of TGF-β RII in the eye by
the Tamoxifen induced CAG Cre x TGF-β RII fl/fl model shows an effect on the
retina thickness. If the average thickness of the whole retina is taken into account
the retina of these mice is significantly thinned (Fig. 3.9 B).
3.3.5 Evaluation of the number of Mu¨ller glia
Increased number of Mu¨ller glia cells in Smad7fl/− mice
Our special interest lies in Mu¨ller glia cells as potential progenitor cells in the
retina. To see if the thickening of the retina and the inner nuclear layer was also
accompanied by a raised number of Mu¨ller glia cells, cryo sections of 3 week old
mice were stained with glutamine synthetase, a Mu¨ller cell marker (Figure 3.10 A).
Cells were counted in 200 µm segments in the peripheral (1), medial (2), and
central (3) retina as described in section 2.4.13 and depicted in Figure 3.10 B.
In Figure 3.11 the numbers of Mu¨ller glia in the central, medial and peripheral
retina are shown. The number of Mu¨ller glia is significantly increased in the
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Figure 3.10: (A) Counting of the Mu¨ller glia was done by performing a glutamine
synthetase staining (green) on sagittal eye sections. The arrows point out two
examples of cell somata of the Mu¨ller glia in the inner nuclear layer (green).
(B) Counting was performed in 200 µm segments in the peripheral (1), medial (2)
and central (3) retina and averaged for both sides of the retina.
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Figure 3.11: Number of Mu¨ller glia in the retina in Smad7-deficient mice: The
number of Mu¨ller glia is significantly increased near the optic nerve head by almost
20% compared to the wildtype littermates (n=9/6, p=0.049).
central retina of Smad7-deficient mice by almost 20 % compared to the wildtype
number.
Number of Mu¨ller glia cells in TGF-β RIIfl/− mice
To see if the TGF-β RII heterozygous deletion also has an influence on the number
of Mu¨ller glia, the cells were counted with the help of a glutamine synthetase
staining as described previously. As can be seen in figure 3.12 the number of
the Mu¨ller glia cells does not vary between the TGF-β RII fl/− and the wildtype
mice. This is consistent with the result of the retina thickness measurement. The
heterozygous TGF-β RII deletion does not appear to influence the cell number in
the retina.
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Figure 3.12: Number of
Mu¨ller glia in the retina of
TGF-β RII fl/− and wildtype
mice: The figure shows the
number of Mu¨ller glia in a 200
µm segment in the peripheral,
medial and central retina of
TGF-β RII fl/− and wildtype
mice. The number of Mu¨ller
cells is not affected by the
heterozygous deletion of TGF-
β RII (n = 5). OS = ora ser-
rata; ONH = optic nerve head.
3.3.6 Proliferation and Apoptosis in newborn Smad7 mice
There are two possibilities why the retina of the Smad7fl/− mice could be thick-
ened; a decrease in cell death or an increase in proliferation. To decide which
effect is dominant we conducted further experiments.
Increase in the number of BRDU positive cells in newborn Smad7fl/− mice
To test for increased proliferation as a possible cause of the thickened retina, 3 day
old Smad7fl/− mice and their wildtype littermates were injected with BRDU and
killed 24 h after injection. The eyes were paraffin embedded and the sections were
stained with an anti-BRDU antibody.
Figure 3.13 shows pictures of the BRDU stained retinae with the BRDU positive
nuclei in green. For quantitative evaluation, the number of BRDU positive cells
in the whole retina was counted. The graph shows the number of BRDU positive
cells per 100 µm in the peripheral, the medial and the central third, and in the
innermost 200 µm of the retina. The number of BRDU positive, and supposingly
proliferating cells, is increased significantly in the innermost 200 µm of the retina.
This is the same area where the retina in the 3 week old mice appears thickened.
We suppose therefore that an increase in proliferation causes the thickening of the
retina.
No increase in TUNEL positive cells in newborn Smad7fl/− mice
To exclude a decrease in cell death as a cause for the thickened retina, TUNEL
stainings were performed. Retinal paraffin sections of 8 day old animals were
simultaneously stained with TUNEL (green staining) and glutamine synthetase
(red staining) (Figure 3.14 A). This way, not only the number of cells undergoing
ontogenetic cell death, but also the ratio of Mu¨ller glia undergoing this process
could be evaluated. The graph in Figure 3.14 B shows that there is no difference
in the number of cells undergoing ontogenetic cell death in Smad7fl/− mice and
their wildtype littermates at day 8. Also the number and percentage of Mu¨ller
glia undergoing apoptosis stays the same at a percentage of 25-30% of all TUNEL
positive cells. We suppose that the heterozygous deletion has no effect on the
ontogenetic cell death in this stage.
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Figure 3.13: Proliferation in 4 day old Smad7-deficient mice: (A) Micrographs
of BRDU stainings (green) in 4 day old Smad7-deficient mice and their wildtype
littermates. At this stage of development the inner nuclear layer is not yet sepa-
rated from the outer nuclear layer. Close to the optic nerve head the number of
BRDU positive cells appears to be elevated. (B) The counting reveals a significant
increase in the number of BRDU positive cells in the inner 200 µm of the retina,
close to the optic nerve head. This is the region were the retina of the 3 week old
Smad7-deficient mice was thickened. In the more peripheral parts of the retina
no significant elevation in the number of BRDU positive cells was found (n=5;
p=0.024).
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Figure 3.14: TUNEL staining in 8 day old Smad7fl/− mice and wildtype con-
trols: (A) The micrographs show a staining for glutamine synthetase (red cell
somata) as Mu¨ller glia marker, and a TUNEL staining to mark apoptotic cells
(green nuclear staining) in sagittal eye sections of Smad7fl/− mice and their wild-
type littermates. Most of the TUNEL positive cells are found in the inner nuclear
layer, marked with an asterisk (*). (B) After counting the TUNEL positive cells
in the whole retina and the TUNEL and glutamine synthetase double positive
Mu¨ller glia, no change in the number of TUNEL positive cells can be seen com-
paring Smad7fl/− mice to their littermates (n = 8/9 (wt/het)). The percentage
of Mu¨ller glia cells undergoing apoptosis stays at 25-30% in both, heterozygous
and wildtype animals.
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Figure 3.15: Relative proliferation rate of rat Mu¨ller glia cells after 24 h TGF-β
1 treatment: (A) Figure A shows that there is no significant difference in prolifera-
tion between treated and untreated cells. (B) In Figure B the results of the single
experiments are shown. Here it can be seen that the 3 different cell isolations
show very different reactions to the TGF-β treatment. While the cells of the first
isolation (bars shown in light gray) show no reaction to the treatment, the third
isolation (bars shown in black) react with a significant elevation in proliferation.
Influence of TGF-β 1 on proliferation in a Mu¨ller glia primary cell culture
Trying to reproduce the proliferative effect of the Smad7 heterozygous deletion
in the young retina in vitro, we worked with Mu¨ller glia primary cell cultures
taken from 8-12 day old rats as described in section 2.7.3. With the help of a
cell proliferation ELISA (section 2.7.4) the effect of a 24 h TGF-β 1 treatment
on the cells was evaluated. The experiment was repeated 3 times with different
primary cultures using two to three 96 well plates for each experiment. As shown
in figure 3.15 A there is no significant difference in the amount of cell proliferation
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between TGF-β 1 treated and untreated cells. Taking a look at the results of the
single experiments (figure 3.15 B), it can be seen that the different cell isolations
show very different reactions to the TGF-β 1 treatment. While the first isolation
showed no reaction, the third showed a significant proliferative effect. All in all,
in this case the primary cell culture does not appear to be a reliable system.
3.3.7 Nestin and GFAP expression
Increased expression of Nestin in Smad7fl/− mice
Increased Nestin expression on protein level in Mu¨ller glia foot processes: As Nestin
is a marker for activated Mu¨ller glia, and stem cells in general, we were interested
in the Nestin expression of Smad7fl/− mice. For the experiment, eyes of 3 week
old mice were used, and sagittal cryo sections were stained with a Nestin antibody.
The Nestin staining (green) was mainly visible in the foot processes of the Mu¨ller
glia covering the ganglion cell layer (Figure 3.16 A). Comparing the intensity of
the staining in Smad7fl/− mice with the staining in wildtype mice, an increase in
intensity was visible mainly in the central retina. To demonstrate this, the staining
intensity was measured with the program ZEN from Zeiss in the foot processes
beneath the nuclei of the ganglion cell layer (section 2.4.12). The measurement
data in Figure 3.16 B shows a significant increase in staining intensity in the
central and medial areas of the retina.
The micrographs in Figure 3.16 C show an example of a double staining of
Nestin (green) and glutamine synthetase (red) in the retina of 3 week old mice.
This was done to demonstrate that the Nestin positive stained processes above the
ganglion cell layer are the foot processes of the Mu¨ller glia cells. The glutamine
synthetase staining (red) of the ends of the foot processes is extremely bright
compared to that of the nuclei of the Mu¨ller glia cells. Because of this, the
staining of the nuclei of the Mu¨ller glia cells is hard to distinguish in the glutamine
synthetase staining. All in all the staining shows that the same cells are stained
with both Nestin and glutamine synthetase and accordingly the Nestin positive
cells and their foot processes are Mu¨ller glia.
Increased Nestin expression on mRNA level in Smad7fl/− mice: To further confirm
this finding, a real-time PCR for Nestin, using the retinae of 3 week old mice
was performed (Figure 3.16 D). Similar to the result of the staining, a significant
increase of Nestin mRNA in the Smad7fl/− mice compared to their wildtype
littermates was found.
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Figure 3.16: (A) Nestin staining of the central and medial retina of 3 week old
mice. The Nestin staining (green) can be seen in the foot processes of the Mu¨ller
glia that border on the vitreous humor. In the figure they are marked with an
asterisk (*). (B) Measurement of Nestin staining intensity with ZEN (n = 6, p=
0.041, p= 0.032). The Nestin staining is significantly stronger in the Mu¨ller glia
foot processes in the central and medial retina of Smad7fl/− mice than in their
wildtype littermates. (C) Double-staining of glutamine synthetase (Mu¨ller cell
marker, red) and Nestin (green). The stainings overlap in the processes and foot
process tips of the Mu¨ller glia. Consequently the Nestin positive cells are Mu¨ller
glia. (D) Nestin real-time data shows a significant increase in the Nestin level of
retinal mRNA of 3 weeks old Smad7fl/− mice (n = 11/9 (wt/het), p = 0.034).
ONL = outer nuclear layer, INL = inner nuclear layer, GCL = ganglion cell layer.
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Figure 3.17: GFAP real-time
data: In untreated mice there
is no significant difference in the
GFAP levels on mRNA level of
Smad7fl/− mice and their wild-
type littermates. (n = 12, p =
0.44).
No increase in GFAP in Smad7fl/− mice: To control if the rise in the Nestin level
is due to a general activation, caused by an irritation in the retina, the GFAP
level of the eyes was checked by real-time PCR. GFAP (glial fibrillary acidic
protein) is a marker of activated Mu¨ller glia and astrocytes. This marker rises
for example during inflammation, lesion gliosis or any irritation of the retina. For
the experiment the retinal RNA of 3 week old mice was used.
As Figure 3.17 shows, there is no significant change in the GFAP mRNA level
in the Smad7fl/− mice. We conclude that there appears to be no general irritation
of the retina.
Expression of Nestin in Mu¨ller glia cells of TGF-β RIIfl/− mice
Evaluation of Nestin expression by immunohistochemistry: The influence of a TGF-
β RII heterozygous deletion on the activity of the Mu¨ller glia cells was tested by
a Nestin staining in 3 week old mice. In unlesioned wildtype mice only the tips
of the foot processes of the Mu¨ller glia facing the vitreous humor are Nestin
positive (Figure 3.18 B). This is not altered by the TGF-β heterozygous deletion.
The measurement data of the staining intensity, depicted in Figure 3.18 A, gave
evidence that there is no difference in Nestin expression between TGF-β RII fl/−
and wildtype mice (n=5).
Evaluation of Nestin and GFAP mRNA level in vivo: To demonstrate the findings of
immunohistochemistry, real-time measurements of the Nestin level in TGF-β RII
fl/− were done. Here, also no significant change in Nestin expression was found
(Figure 3.19 A). Controlling the GFAP level to look for a general activation in the
retina, a tendency to an increased GFAP level was found in TGF-β RII fl/− mice.
This could point to a general activation or irritation caused by the deficiency of
TGF-β RII.
Nestin expression in vitro after TGF-β 1 treatment
As an in vitro test system primary rat Mu¨ller cell cultures were used. We were
interested to see if a 24 h TGF-β 1 treatment could have the same effect on the
Nestin expression as the Smad7 deficiency had. As can be seen in figure 3.20 the
Nestin mRNA level does not rise in vitro after 24 h TGF-β 1 treatment. As the
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Figure 3.18: Nestin expression in untreated TGF-β RIIfl/− mice: (A) The rel-
ative Nestin expression in the Mu¨ller glia foot process tips was measured with
the program ZEN from Zeiss in the medial and central retina. (B) The micro-
graphs show the nuclei of the ganglion cell layer (blue) with the Mu¨ller glia foot
processes (green) that border on the vitreous humor. The micrographs as well
as the measurement in Figure A reveal no difference in Nestin expression in the
foot processes of the Mu¨ller glia cells (n = 5). INL = inner nuclear layer, GCL =
ganglion cell layer.
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Figure 3.19: Figure A shows the real-time data of the Nestin and GFAP ex-
pression in TGF-β RII fl/− mice and their wildtype littermates. Supporting the
findings of the immunohistochemistry experiments, no alteration in the Nestin
levels was found (n = 5). The GFAP real-time data in Figure B reveals a trend
to an increased GFAP level in the TGF-β RII fl/− mice. This could point to a
general activation or irritation of the retina (n = 6, p = 0.057).
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Figure 3.20: Nestin mRNA
level in primary rat Mu¨ller
glia culture after 24 h TGF-
β 1 treatment: No change in
Nestin level between TGF-β 1
treated and untreated Mu¨ller
cells was found.
Nestin levels react to every lesion, it is possible that the levels in isolated Mu¨ller
cells are already elevated, and can not be stimulated any further.
3.3.8 Activated pathways in Smad7fl/− mice
As recent publications showed, a Smad7 deficiency could not only modulate the
TGF-β pathway, but also the EGF pathway [152]. An increased EGF signaling
would be a reasonable cause of increased proliferation in the retina. With this
in mind, experiments were conducted to show if the TGF-β pathway is activated
and if the EGF pathway plays a role causing the shown phenotype.
Activation of the TGF-β pathway - increase of pSmad3 in Smad7fl/− mice
To examine the activation of the TGF-β pathway, western blot analysis for pSmad3,
a receptor regulated Smad of the TGF-β pathway, was performed. The proteins
used for the experiment were isolated from the retinae of 3 week old mice. The
level of pSmad3 was markedly raised in the Smad7fl/− mice (n = 4/5) (Fig-
ure 3.21). This indicates an activation of the TGF-β pathway. The housekeeper
gene GAPDH was used as a control.
pSmad3  (52 kDa)
GAPDH  (37 kDa)
fl/-
Smad7 wildtype
Figure 3.21: Western blot analysis of
pSmad3: The protein pSmad3 was in-
creased in Smad7fl/− mice compared
to their wildtype littermates (n = 4/5
(wt/het)).
No alterations in the EGF pathway in Smad7fl/− mice
To examine an activation of the EGF pathway western blot experiments were
conducted. As the experiments show, important proteins involved in the EGF
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signaling like ERK, Akt are not altered in expression respectively phosphoryla-
tion (figure 3.22). Most likely the EGF pathway is not influenced by the Smad7
deficiency.
pERK (44,42 kDa) Akt (60 kDa) pAkt (60 kDa)
GAPDH (37 kDa) GAPDH GAPDH
wildtypeSmad7 
fl/-
wildtypeSmad7 
fl/-
wildtypeSmad7 
fl/-
Figure 3.22: Western blot for pERK, Akt and pAkt on retina protein of 3 week
old Smad7fl/− mice and wildtype littermates: None of the components of the
EGF signaling is altered in expression or phosphorylation (n = 5/4).
3.4 NMDA lesions in Smad7 and TGF-β RII defi-
cient mice
It is well documented, that under certain conditions retinal lesion models like
NMDA lesions or light damage lead to an activation of retinal progenitor cells
and even promote proliferation. Accordingly we performed lesion experiments in
Smad7fl/− and TGF-β RIIfl/− mouse models.
3.4.1 Axon number after an NMDA lesion
No effect on axon count after NMDA injection in Smad7fl/− mice
Before any experiments concerning the proliferation in the retina were conducted,
we wanted to examine an eventual influence of the heterozygous deletion on cell
death in the retina.
To analyze the influence of a lesion on cell death in Smad7fl/− mice, the axon
number in the optic nerve after a lesion with NMDA was evaluated. For the
experiment 6 week old mice were injected with NMDA in one eye and PBS, as
a control, in the other eye. 3 weeks after the injection the mice were killed and
epon semithin sections of the optic nerve were stained to count the number of
axons via light microscopy. At this time after the lesion, most of the apoptotic
ganglion cells and accordingly most of the killed axons were abolished. Examples
for micrographs of PBS and NMDA treated nerves can be seen in Figure 3.23.
As shown in Figure 3.24, no significant difference in axon number could be found
between the Smad7fl/− mice and the wildtype littermates, neither after NMDA
injection nor after PBS Injection. Smad7fl/− mice as well as wildtype animals
react to the NMDA injection with loss of about 60% of axons.
No effect of TGF-β RII heterozygous deletion on axon number after NMDA
lesion
By counting the axon number in the optic nerve after NMDA lesion, we also
evaluated the influence of the heterozygous TGF-β RII deficiency on apoptosis in
the retina.
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Figure 3.23: Morphology of a cross section of the optic nerve in Smad7fl/− mice:
Smad7fl/− mice and their wildtype littermates show no apparent difference in the
morphology of PBS and NMDA treated optic nerves (PBS n = 3, NMDA n = 3).
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Figure 3.24: Axon count in NMDA treated Smad7fl/− mice: Smad7fl/− mice
and their wildtype littermates show no difference in axon number in the optic
nerve in PBS and NMDA treated eyes. In Smad7fl/− and wildtype mice after
NMDA injection about 60% of the axons are lost (PBS n = 3, NMDA n = 3).
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Figure 3.25: The micrographs of the optic nerve of TGF-β RII and wildtype
mice show no morphological differences, neither in the PBS treated nor in the
NMDA treated nerves (PBS n = 3, NMDA n=3).
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Figure 3.26: Total axon count of the optic nerves: In both genotypes, TGF-β
RIIfl/− and wildtype, the axon number is about 75 % lower after the NMDA
lesion. The TGF-β RII deficiency has no influence on the axon count, neither in
PBS treated nor in NMDA treated optic nerves (PBS n = 3, NMDA n=3).
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As in the Smad7fl/− mice, the eyes were injected with NMDA respectively PBS
at an age of 6 weeks and were killed 3 weeks later. Epon sections of the optic
nerve were used to count all axons in the PBS and NMDA treated nerves. The
micrographs of TGF-β RII fl/− mice and wildtype mice show no difference in the
morphology of the optic nerves, neither in PBS treated nor in the NMDA treated
nerves (Figure 3.25). Figure 3.26 reveals the actual axon numbers. The axon
number in TGF-β RIIfl/− mice and wildtype littermates is at the same level in
PBS treated eyes and is reduced by about 75% in NMDA treated eyes for both,
TGF-β RIIfl/− and wildtype mice. We conclude that the heterozygous deletion
of TGF-β RII has no influence on the axon number after a lesion.
3.4.2 Retinal apoptosis after an NMDA lesion
Smad7 deficiency does not influence the amount of apoptosis after an NMDA
lesion.
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Figure 3.27: TUNEL staining (green) in NMDA treated retinae: As expected the
NMDA lesion causes apoptosis in ganglion cells and also in the inner nuclear layer.
Comparing Smad7fl/− mice and their wildtype littermates there are no obvious
differences in the amount or distribution of TUNEL positive nuclei (green). ONL
= outer nuclear layer, INL = inner nuclear layer, GCL = ganglion cell layer.
To back up the result of the axon counting, and to see the effect of the Smad7
deficiency on apoptosis in the retina after a lesion, TUNEL assays were performed.
These immunohistochemical assays stain the nuclei of apoptotic cells and were
performed on sagittal retina sections, an example is shown in Figure 3.27. The
TUNEL stained nuclei appear in green. For the sections, 6 week old mice were
killed 24 h after NMDA injection. The sagittal cryo sections were TUNEL stained
and TUNEL positive cells in both halves of the retina were counted and averaged
for each eye. Figure 3.28 A shows a diagram with the number of TUNEL positive
cells in half a retina, 3.28 B depicts the TUNEL positive cells of outer nuclear
layer, inner nuclear layer and ganglion cell layer.
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Figure 3.28: TUNEL positive cells after NMDA injection in Smad7fl/− mice
and their wildtype littermates. (A) Number of TUNEL positive cells in half of a
retina: No significant difference in the number of TUNEL positive cells between
the wildtype littermates and the Smad7 deficient mice is visible. (B) Number
of TUNEL positive cells in different layers: ONL = outer nuclear layer; INL =
inner nuclear layer; GCL = ganglion cell layer. There is no obvious difference in
the number of TUNEL positive cells in the different retinal layers comparing the
Smad7 deficient with the wildtype mice (PBS n=6, NMDA n=5).
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The number of TUNEL positive cells in the whole retinae of the Smad7 deficient
mice, as well as in the single retinal layers, showed no significant difference to the
wildtype animals. It appears that the heterozygous deletion has no effect on the
apoptosis after a lesion in the eye. Remarkably the NMDA lesion does not only
damage the ganglion cell layer, but also the inner nuclear layer and even the outer
nuclear layer, see Figure 3.28 B.
TGF-β RII deficiency does not influence the amount of apoptosis after an
NMDA lesion
The apoptosis rate after NMDA lesion was also checked for TGF-β RII deficient
mice, using TUNEL stainings like for the Smad7 deficient mice.
In Figure 3.29 A the data for TUNEL positive cells of the whole retina for the
TGF-β RII deficient mice and the wildtype mice is shown. The data reveals no
difference in apoptosis caused by the heterozygous deletion. The data for the
different layers, see Figure 3.29, shows that not only the ganglion cell layer but
also especially the INL is heavily damaged after an NMDA lesion. The more
detailed data still reveals no difference between the TGF-β RIIfl/− mice and the
wildtype.
3.4.3 Proliferation after NMDA treatment
No proliferation after NMDA injection in Smad7fl/− mice
Karl et al. demonstrated that proliferation in mice can be induced by a lesion in
the eye under special conditions [40]. To provoke a possible proliferative reaction
in the retinae of Smad7fl/− mice, 6 week old animals were lesioned with NMDA. To
test for a possible proliferative reaction, BRDU was injected intraperitoneally at
the time of the NMDA eye injection. After 24 h the mice were again injected with
BRDU and killed 24 h after this last BRDU injection as depicted in Figure 3.30.
Sagittal cryo sections of the cryo embedded eyes were stained for BRDU. Despite
the high animal number of 9 mice per group no BRDU positive cells could be
found in the mice retinae. We conclude that there appears to be no influence of
the Smad7 deficiency on the proliferative reaction after lesion.
No proliferation after NMDA lesion in TGF-β RIIfl/− mice
To see if the heterozygous deletion of TGF-β RII allows a proliferative reaction
after lesion, experiments were conducted with two different time delays between
injection and killing of the mice.
For the first experiment the mice that had been used for the TUNEL experiment
(3.4.2) were additionally injected with BRDU at the day of NMDA injection and
killed 24 h later. This way the reaction after 24 h and a possible connection with
the ongoing apoptosis could be tested, as the sections of the mice were also stained
for TUNEL positive cells.
As the retinae of the mice killed 24 h after NMDA injection were examined for
BRDU positive cells, only three of eleven animals (6 wt/5 het) showed sporadic
positive cells in the outer nuclear layer. Examples are shown in Figure 3.31. These
were the same animals that revealed the strongest lesion in the outer nuclear layer
in the TUNEL experiment, but the reaction did not depend on the genotype. In
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Figure 3.29: Figure A shows the number of TUNEL positive cells in TGF-β
RII deficient mice after NMDA/PBS injection averaged over both halves of the
retina. There are no significant differences in the number of TUNEL positive cells
comparing TGF-β RII to wildtype mice, neither in the PBS, nor in the NMDA
treated retinae. In Figure B the detailed number of TUNEL positive cells in
different layers of the retina is shown. Besides the expected lesion on the ganglion
cell layer, the NMDA lesion causes a vast lesion in the inner nuclear layer, but the
TGF-β RII heterozygous deletion has no influence on the number or distribution
of dying cells (n = 6/5 (wt/het)). ONL = outer nuclear layer; INL = inner nuclear
layer; GCL = ganglion cell layer.
3.4. NMDA LESIONS IN SMAD7 AND TGF-β RII DEFICIENT MICE 83
NMDA
BRDU
day1 day2 day3
BRDU preparation
Figure 3.30: Scheme of NMDA and BRDU injections.
20µm 
Figure 3.31: BRDU positive cells in the outer nuclear layer of NMDA lesioned
TGF-β RII- deficient mice 24h after NMDA injection: The cells show up in ani-
mals with a strong lesion of the outer nuclear layer, independent of the genotype
and disappear 2 days after injection. This appears to be a effect of DNA repair.
11 animals only one BRDU positive Mu¨ller glia cell was found. For the second
experiment TGF-β RII deficient mice and wildtype littermates were killed two
days after the NMDA injection as depicted in figure 3.30 like in the Smad7 model
(n = 6 wt/11 het). In these retinae, no BRDU positive cells were found in the outer
nuclear layer. Some scattered BRDU positive cells were found in the ganglion cell
layer.
3.4.4 Nestin and GFAP expression after NMDA treatment
Nestin and GFAP expression after NMDA treatment in Smad7fl/− mice
A possible influence of the Smad7 deficiency on the activation of Mu¨ller glia cells
can be analyzed by performing a Nestin staining after the NMDA lesion. For the
experiment, 6 week old mice were injected with NMDA and killed 3 days later.
The effect of an NMDA treatment on the Nestin level of the Mu¨ller glia cells
can be seen for example in Figure 3.32 where the processes of the Mu¨ller glia
cells appear in green (Nestin) after the NMDA lesion. This points to an increased
Nestin expression after the NMDA injection, which is a well known reaction after
any lesion in the eye. For a statistical analysis, the stainings were rated with the
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Figure 3.32: Nestin and GFAP expression after NMDA lesion in Smad7fl/−
mice: (A) Nestin staining after NMDA/PBS injection: Comparing the staining
after PBS and after NMDA injection, it can be seen that the Nestin level in the
Mu¨ller glia foot processes (marked with an asterisk (*)) rises significantly after
NMDA injection. (B) Using the scoring method, it could be shown that the
Nestin level rises significantly in the wildtype mice, but not in the Smad7fl/−
mice. This is owed to the higher base level of the Nestin staining in the PBS
treated Smad7fl/− mice eye, that was already found in 3 week old mice, see
section 3.3.7 (n= 7/4/4/4, p = 0.042). (C) The micrographs in this figure show
an obvious elevation in GFAP expression in Mu¨ller glia cells after NMDA injection
in Smad7fl/− mice and their wildtype littermates. This is a well known reaction
of Mu¨ller glia cells to a lesion. The Smad7 deficiency itself appears to have no
influence on the GFAP expression and accordingly on the activation of the Mu¨ller
glia cells. As the focus lay on the Mu¨ller glia cells the staining in the ganglion
cell layer, caused by GFAP positive astrocytes was not taken into account in the
scoring. (D) The GFAP level was evaluated using the scoring method because of
the background staining (n = 5/4/4/4, p = 0.037). ONL = outer nuclear layer;
INL = inner nuclear layer; GCL = ganglion cell layer.
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Figure 3.33: (A) The micrographs show Nestin stained retinae from TGF-β
RIIfl/− mice and their wildtype littermates. After NMDA injection, only a slight
reaction in the form of Nestin expression is visible in the Mu¨ller glia foot processes
(marked with an asterisk (*))in TGF-β RIIfl/− mice and wildtypes. (B) With the
scoring method, it can be seen that the heterozygous TGF-β RIIfl/− mice show
a significant rise in Nestin expression. No significant difference can be found
after the NMDA injection in wildtype mice. (C) Micrographs in this figure show
a GFAP staining after an NMDA injection in TGF-β RII deficient mice and
their wildtype littermates. The strong reaction of both, TGF-β RIIfl/− mice and
wildtype littermates, to NMDA can easily be seen. (D) Using the scoring method,
the GFAP staining intensity can be compared. In the wildtype littermates as well
as in the TGF-β RII deficient mice a significantly higher GFAP expression can be
found after NMDA injection, but the TGF-β RII deficiency does not appear to
influence the GFAP expression. ONL = outer nuclear layer; INL = inner nuclear
layer; GCL = ganglion cell layer.
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scoring method, as described in sec. 2.4.12. This method is used when background
stainings have a strong influence on the result of intensity measurements.
The graph in Figure 3.32 shows that the Nestin level rises significantly after
an NMDA injection in wildtype mice. It also rises in Smad7fl/− mice but not
to a significant level. There appears to be no significant influence of the Smad7
deficiency on the reaction and activation of the Mu¨ller glia cells.
This experiment has also been done in an analogous way for GFAP (Fig-
ure 3.32). Here, the well documented rise in expression of GFAP after a lesion
could also be found. But as in the experiment with Nestin, no significant difference
between the Smad7fl/− and the wildtype mice can be seen.
Nestin and GFAP expression after NMDA treatment in TGF-β RIIfl/− mice
The experiments were also carried out for the TGF-β RII deficient animals (Fig-
ure 3.33). Besides the anticipated increase of expression of Nestin and GFAP
following the NMDA injection, no difference in reaction caused by the TGF-β RII
deficiency could be found. We conclude that a deficiency of TGF-β RII has no
influence on the activation of Mu¨ller glia cells after an NMDA lesion.
3.5 β-B1-CTGF overexpressing mice
As Connective tissue growth factor (CTGF) is a target protein of the TGF-β
pathway, and is usually upregulated when the TGF-β pathway is activated, we
wanted to see if an overexpression of CTGF in the eye had the same effect as
a Smad7 deficiency. For this purpose mouse models were used that overexpress
CTGF to different levels in the lens. Strain 1 has a low level of expression of
CTGF, in Strain 5 the expression is higher and Strain 6 shows the highest levels.
The strains were bred and provided by Benjamin Junglas and Rudolf Fuchshofer
[153].
3.5.1 Increased retinal thickness
Interestingly the overexpression of CTGF leads to an impressive thickening of the
retina. This effect is starting at the central retina in strain 1 where CTGF is
expressed at low levels, and spreads over the whole retina as the CTGF levels
rise in strains 5 and 6, see Figure 3.34. In strain 6 the retina of the CTGF
overexpression mice is more than 20% thicker than in the wildtype animals. The
effect of this dose dependent thickening can also be seen in the inner nuclear layer,
which is also more than 20% thicker in strain 6 animals than in the wildtype mice.
3.5.2 Number of Mu¨ller glia cells
As the inner nuclear layer was thickened, we were interested in the number of
Mu¨ller glia analogous to the experiments on Smad7fl/− mice. Again 3 week old
mice were used and the counting was done with the help of a glutamine synthetase
staining. Also, counting and statistics were done analogous to the experiments
with the Smad7 mice. But contrary to the Smad7 mice, no significant effect on the
number of Mu¨ller glia was found in these mice, regardless of expression intensity.
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Figure 3.34: Measurement of retina thickness in different Connective tissue
growth factor (CTGF) overexpressing strains. The thickening effect of the whole
retina and the inner nuclear layer rises with the CTGF expression in the different
mouse lines (strain 1: n = 6/6; strain 5: n = 7/6; strain 6: n = 3/3; p < 0.05).
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Figure 3.35: The number of Mu¨ller glia cells was evaluated in the central (close
to the optic nerve head), medial and peripheral (close to the ora serrata) retina
of the three CTGF overexpressing strains. In none of the strains a significant
difference could be found. The number of Mu¨ller glia is not influenced by an
overexpression of CTGF (strain 1: n= 4/6, strain 5: n= 6/5, strain 6: n = 4/3,
p < 0.05). OS = Ora serrata; ONH = optic nerve head.
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Figure 3.36: (A) Real-time PCR for CTGF in 3 week old Smad7fl/− mice:
The mRNA level of CTGF is not significantly altered in Smad7fl/− mice (n =
12/11 (wt/het)). (B) Western blot for CTGF with retina protein from 3 week
old Smad7fl/− mice and wildtype littermates: Similar to the result of the real-
time PCR, the CTGF protein level is not altered in the Smad7fl/− mice. The
housekeeper β-actin was used as a control (n = 4/5 (wt/het)).
No alteration in CTGF levels in Smad7fl/− mice
As CTGF is a target gene of the TGF-β pathway we speculated that the thickening
in the retina of the CTGF overexpressing mice could be the same effect as seen in
the Smad7fl/− mice. Since we did not observe changes in the number of Mu¨ller
cells in the CTGF overexpressing mice, the CTGF level of 3 week old Smad7fl/−
mice and their littermates was evaluated by quantitative real-time PCR using
retinal RNA.
As Figure 3.36 A shows, no significant change could be found in the level
of CTGF. Western blot analysis for CTGF showed no difference in the protein
levels between the wildtype animals and the Smad7 deficient mice as well (fig-
ure 3.36 B), indicating that the proliferative effect, seen in the Smad7 deficient
mice is not mediated through CTGF elevation. Nevertheless CTGF itself could
possibly promote neuronal survival or increased proliferation, since the ONL and
the INL are significantly thicker in those animals compared to the wildtype. But
this could as well be an effect of increased extracellular matrix.

Chapter 4
Discussion
Based on the results presented in chapter 3, we conclude that TGF-β signaling has
a significant effect on proliferation. It influences proliferation during development
of the central retina, but its alteration does not provoke proliferation in the normal
and injured adult retina. This conclusion rests upon:
• the generation of genetically modified mouse models, with a diminished or
enhanced overall TGF-β signaling during development.
• the finding of an increase in the number of Mu¨ller glia along with enhanced
thickness of the inner nuclear layer in mice with enhanced TGF-β signaling.
• the observation of increased proliferation during the development of the
postnatal retina at P4, where the peak of Mu¨ller glia proliferation is ob-
served, and the absence of influence on programmed cell death in retinal
development in these mice.
• the increased expression of Nestin, a progenitor cell marker, in the central
retina at P20 in mice with enhanced TGF-β signaling.
• the almost complete lack of Mu¨ller cell proliferation after exitotoxic damage
in animals with diminished or enhanced TGF-β signaling.
In the following, we will discuss these results in detail.
4.1 Generation of mouse models with diminished or
enhanced TGF-β signaling
With the help of the Cre LoxP system we were able to generate a mouse model
deficient for Smad7, an inhibitor of TGF-β signaling, by deleting the floxed pro-
moter region and exon I using the EIIa Cre recombinase. It was not possible to
work with a homozygous deletion, because this turned out to be lethal at a late
embryonic stage. The Smad7 deficiency could be demonstrated on mRNA level.
Additionally, we could show by western-blot analysis for pSmad3, a receptor reg-
ulated Smad of the TGF-β pathway, that the TGF-β signaling in these animals
was enhanced.
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To generate a comparable model for a diminished TGF-β pathway, we used an
analogous model to create TGF-β receptor II deficient mice by a heterozygous
deletion of exon II of TGF-β receptor II. The TGF-β receptor II deficiency could
be shown on protein level.
4.2 Influence of an altered TGF-β signaling on reti-
nal thickness and cell number
4.2.1 Smad7 deficiency causes a thickened retina around the
optic nerve head
In our study, the heterozygous deletion of Smad7 lead to a significantly thickened
central retina at P20, including a thickened inner nuclear layer with an elevated
number of Mu¨ller glia, as well as a thickened outer nuclear layer pointing to an
increased number of photoreceptors. It is well possible that increased numbers of
bipolar cells, amacrine cells or horizontal cells also contribute to the thickening of
the inner nuclear layer.
The findings displayed show that an alteration of the TGF-β pathway affects
different cell types in the retina. It is therefore tempting to speculate that this
effect occurs very early in development, affecting the common progenitor cells of
neurons and glia.
4.2.2 Induceable TGF-β RII homozygous deletion causes a
thinned retina
As the heterozygous TGF-β RII deletion had no effect on retina thickness, we
worked with an induceable mouse model with a homozygous deletion for TGF-β
RII. For this mouse model, Tamoxifen induceable CAG Cre mice were crossed
with TGF-β RIIfl/fl mice. The mice were bred and kindly provided by Barbara
Braunger. The resulting induceable homozygous deletion of TGF-β RII in the
retina caused an overall thinned retina. This appears to be an effect contrary to
the retina thickening in the Smad7fl/− mice.
4.3 Influence of the TGF-β pathway on proliferation
and stem cell renewal
4.3.1 Increased proliferation in Smad7 deficient mice
Since the number of Mu¨ller cells was significantly elevated in the Smad7 deficient
mice, we decided to investigate a possible pro-proliferative effect of the deficiency.
For these experiments, P4 as the natural peak of Mu¨ller glia cell proliferation was
chosen. Indeed, a significantly raised number of BRDU positive cells was found in
the central retina of four day old mice. This indicates an increased proliferation
as the cause of the thickened retina. An alteration in the apoptosis rate in the
retinae could not be found at P8, the peak of Mu¨ller glia apoptosis. This, however,
does not exclude a changed apoptosis rate in other stages of development.
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enhanced prolonged decelerated
self renewal proliferation proliferation
more BRDU positive cells + = +
increased final cell number + + =
Table 4.1: An increased number of BRDU positive cells can be caused by en-
hanced self renewal or decelerated proliferation. An increased final number of
cells can originate from enhanced self renewal and a prolonged proliferation pe-
riod. Only an enhanced capacity for self renewal can cause both effects.
For the determination of the exact effect of Smad7 deficiency on cell prolifer-
ation, we gathered two main data points: In P20 we found an elevated number
of Mu¨ller glia and a thickened retina, while in P4 an elevated number of BRDU
positive cells was found.
Considering cell proliferation as cause for the elevated final number of retinal
cells in P20, two effects could be responsible: The phase of proliferation could
be prolonged in the retina of the newborn animal, or more stem cells could be
proliferating in the same time frame. Both would lead to a higher final cell count
in the retina of the adult animal. If we assume the same starting amount of cells,
an increased number of proliferating cells at the same time can only be caused by
an enhanced ability for self renewal.
Regarding the proliferation data in P4, the increased number of BRDU positive
cells could also have two different reasons. On the one hand, single stem cells could
require a prolonged time for one cell cycle, and in this way more cells could be
seen proliferating at once. This would, however, not lead to an increased final cell
count.
On the other hand, the cells could proliferate at normal speed but undergo
additional rounds of proliferation, pointing to an enhanced self renewal capacity.
This would also lead to an increased number of BRDU positive cells at any given
time, if one assumes the same starting amount of stem cells.
Considering both, P4 and P20 data, we conclude that an enhanced self renewal
capacity of the stem cells can explain our findings, see Table 4.1. This does not
exclude that the timespan of proliferation could be additionally prolonged in the
Smad7 deficient mice.
4.3.2 Direct effects of TGF-β on adult neural cells and embry-
onic stem cells
In our study, deficiency of Smad7 and enhanced TGF-β signaling lead to a thick-
ened retina, increased proliferation and supposedly enhanced stem cell renewal.
Contrary to this, most publications working with effects of TGF-β on adult
neural stem cells show TGF-β as an inhibitor of stem cell proliferation [70,88,100]
or as a protector of stem cell quiescence [154]. TGF-β also had an anti-proliferative
effect in vitro in retinal postnatal progenitors [102].
On the other hand, TGF-β was shown to have pro-proliferative effects and
influences differentiation in embryonic stem cells: Watabe et al. showed that the
treatment of ES cells with an inhibitor for type I receptor kinases (e.g. TGF-β RI),
lead to a decrease of proliferation. This suggests that TGF-β, activin or nodal
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is needed for the proliferation of embryonic stem cells [94]. In undifferentiated
human embryonic stem cells TGF-β, activin or nodal signaling were observed,
and their expression decreased upon early differentiation [95]. An inhibition of
the TGF-β/activin/nodal signaling by SB431542 resulted in decreased expression
of markers of undifferentiated cells [96–98]. This implies that TGF-β keeps the
stem cells from differentiating and therefore supports self renewal.
The effects on proliferation and differentiation are similar to the ones occurring
in our Smad7fl/− mice. This suggests that the retina is thickened due to an effect
on early stem cells. The described facts can be brought into line if one assumes
that the retinal stem cells change their reaction to TGF-β in a certain phase of
differentiation, as implied by the earlier findings described above.
Besides a direct effect of the altered TGF-β pathway, it is also possible that
Smad7 or other components of the TGF-β pathway interact with other pathways
or act through other mediators.
4.3.3 CTGF as a potential mediator
Connective tissue growth factor (CTGF) has been identified as a critical down-
stream mediator of TGF-β [155] signaling acting on the proliferation of connective
tissue cells. It is additionally known to have a proliferative role in some cancer
cell lines [156].
In a further part of our studies, mice with an overexpression of the connective
tissue growth factor (CTGF) in the lens showed an extremely thickened retina
similar to the less pronounced phenotype seen in the Smad7fl/− mice. With rising
concentrations of CTGF in CTGF overexpressing mouse strains, the thickening
starts at the optic nerve head and gradually spreads until the whole retina is
affected in the mouse strain with the highest CTGF expression.
These findings led to the hypothesis that the thickened retina in the Smad7fl/−
mice could be caused by a stronger TGF-β signaling and in turn a stronger CTGF
signaling resulting in enhanced cell proliferation in the retina.
Contrary to this hypothesis, the CTGF overexpressing mice showed no differ-
ence in the number of Mu¨ller glia as the Smad7 deficient mice did, even as the
retina was much more thickened than in the Smad7 deficient mice. This again
could be evidence that the mechanisms leading to thickening in both cases are
different from each other. It is for example well possible, that the thickening of
the retina of the CTGF overexpressing mice can not be explained by a higher cell
mass but by a expression of matrix proteins like proteoglycan. The proposition
that both effects are of different origin is supported by the fact that in real-time
PCR no elevated level of CTGF could be found in the retinae of Smad7fl/− mice
at P20.
4.3.4 Possible influence of an crosstalk between TGF-β and
EGF-pathway on proliferation
Krampert et al. found that Smad7 modulates the neural stem/progenitor cell pro-
liferation TGF-β- and BMP-independently in the brain [157]. They showed that
enhanced proliferation after a Smad7 Exon1 deletion might be at least partially
mediated by elevated signaling via the epidermal growth factor (EGF) receptor,
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Figure 4.1: Crosstalk between the Wnt pathway and the TGF-β pathway during
the activation of Xtwn, a target gene (Figure adapted from: [161]).
as the mutant cells showed higher expression and activation levels of the EGF
receptor. Additionally this proliferation could be reduced by an EGF receptor
inhibitor.
Also in cancer cells, which often act similar to stem cells, TGF-β was found to
stimulate proliferation in some cases by crosstalk with the EGF pathway. Colon
carcinoma cells for example are stimulated to proliferate by TGF-β via a Ras
dependent mechanism [158,159].
Having these findings in mind we tested the Smad7fl/− mice for an activation
of the EGF pathway by using western blot experiments. It could be shown that
important proteins involved in the EGF signaling like ERK and Akt were neither
altered in expression nor phosphorylation. The EGF pathway is therefore most
likely not altered by Smad7 deficiency.
4.3.5 Possible influence of an crosstalk between TGF-β and
Wnt-pathway on proliferation
An interesting further potential cause for the increased proliferation in the Smad7
deficient mice is the crosstalk between the wingless Type (Wnt)-pathway and the
TGF-β pathway. The Wnt-signaling pathway is a known modulator of stem cell
maintenance, cellular proliferation and differentiation [160].
Briefly, in the absence of Wnt signaling, glycogen synthase kinase 3 (GSK-3)
phosphorylates β-catenin. This induces ubiquitination and degradation of β-
catenin. When Wnt signaling is activated, GSK-3 activity is inhibited and β-
catenin can accumulate and translocate to the nucleus. In the nucleus it associates
with members of the lymphoid enhancer binding factor family (LEF/TCF). These
are DNA binding proteins that activate targets of the Wnt pathway in association
with β-catenin. Letamendia et al. showed that Smads physically interact with
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LeF1/TCF and in this way cooperate to express Xtwn, a Wnt and TGF-β target
gene (Figure 4.1) [161].
Taking the crosstalk between the two pathways into consideration, a hypoth-
esis would be that a downregulation of the TGF-β pathway could cause a com-
pensating upregulation of the Wnt pathway, resulting in an enhanced stem cell
maintenance and a thickened retina due to enhanced stem cell renewal.
4.4 The possible role of Nestin in the progenitor cell
population
4.4.1 Increased Nestin expression in Smad7 deficient mice
In Smad7fl/− mice an increased expression of Nestin, an important marker for
neural stem/progenitor cells, was found at P20 in the central retina. This applies
particularly to the foot processes of the Mu¨ller glia, facing the vitreous body, and
was demonstrated in immunohistochemistry as well as on RNA level.
4.4.2 Nestin expression as a sign of activation, gliosis and
structure stabilization
In general an increased Nestin expression is considered a sign of active Mu¨ller glia
cells, e.g. going into gliosis or preparing for migration or proliferation. Together
with an increased GFAP level it could point to a gliotic reaction, but the GFAP
RNA level was not increased in the retinae of these mice. In the case of gliosis,
Nestin works as a stabilizing element that supports the retinal structure, e.g.
following a lesion.
4.4.3 Polarized distribution of cell components
Besides stabilizing the cell structure, as cytoplasmatic protein, Nestin is also as-
sumed to be involved in the asymmetric distribution of material between dividing
stem cells and their differentiating daughter cells [120]. In this process Nestin
itself, other cytoskeletal proteins and cellular factors are shared unequally be-
tween the daughter cells, making them follow different paths during development.
This applies according to Bieberich et al. for Nestin in the neural tube, where
ventricular cells continue to proliferate, while differentiated cells migrate to the
surface.
In these cells the polarized distribution of material between dividing and differ-
entiating cells appears to be caused by Nestin mediated disassembly and uneven
partitioning of motile vimentin particles during mitosis [106, 162–164]. Following
this observations we propose that Nestin could also influence the stemness of stem
cells in the murine retina.
4.4.4 The possible role of Nestin in cell cycle control
Interestingly the significantly elevated Nestin expression is exactly in the same
area as the elevated proliferation at P4. Therefore we suppose that Nestin could
be involved in the control of the cell cycle in the progenitor cell population. A
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fact supporting this hypothesis is that Nestin is known to play a major role in
the stem cell renewal of neural stem cells: Park et al. found in their study that a
Nestin knockout lead to the development of fewer neural stem cells in the neural
tube [125].
Additionally it is known that Nestin constitutes a dynamic scaffold for the Cdk5
complex, which is responsible for the withdrawal from the cell cycle [107]. Nestin
also has the ability to halt the differentiation of the myoblasts in vitro when it
is overexpressed, by interacting with the Cdk5/p35 complex and controlling the
cleavage of p35 to its degradation resistant form p25 [126].
To demonstrate these effects of Nestin in a Mu¨ller glia cell culture is difficult. As
soon as a lesion occurs, Mu¨ller glia strongly express Nestin. For this reason Mu¨ller
glia in cell culture show a much stronger Nestin expression than the unlesioned
retina, where nearly no Nestin expression can be found in the retina of wildtype
animals. This may also be the reason why a treatment with TGF-β in our studies
could not further elevate the level of Nestin produced by the Mu¨ller glia in culture.
Therefore the evidence for this hypothesis would have to be adduced by additional
experiments in the in vitro models, for example by western blot analysis for the
p35 and p25.
4.4.5 Nestin expression after NMDA lesion
After NMDA lesion in general, a tendency for increased levels of Nestin and GFAP
can be seen in the experiments. This is a long known effect following lesions in the
retina and appears to point to a beginning gliosis in the retinae. As this happens
in wildtype animals as well as in animals with an altered TGF-β pathway, this
reaction appears to be unrelated to the gene deletions and does not appear to
influence the reactivity of the Mu¨ller glia cells in TGF-β RII/Smad7 deficient
mice regarding proliferation and regeneration.
4.5 Influence of TGF-β signaling on proliferation in
the lesioned adult retina
In our studies, sporadic BRDU positive cells were found in the outer nuclear layer
of three of eleven tested TGF-β RII deficient mice, 24 h after NMDA lesion. Only
one animal showed a single BRDU positive Mu¨ller glia cell. This reaction did
not depend on the genotype of the mice (6 wt/5 het). When using these samples
for a TUNEL assay, the same samples that showed BRDU positive cells revealed
the highest number of TUNEL positive cells in the outer nuclear layer. While it
is possible that Mu¨ller glia cells translocate in the direction of the outer nuclear
layer, this movement takes several days according to Joly et al. [165]. In our
study, the BRDU positive cells appeared one day after the NMDA injection and
had disappeared in samples taken two days after the injection.
A possible explanation for these results can be found in the publication by Joly
et al. [165]. They describe the occurrence of BRDU positive cells in the outer
nuclear layer one day after light damage and the disappearance of these cells after
two to three days. Joly et al. could explain this phenomenon as a DNA repair
reaction by costaining the BRDU positive cells with ligase IV, a marker for DNA
repair. As the results appear very similar to ours, even in their dependence on
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a lesioned outer nuclear layer, we assume that the BRDU positive cells in our
samples can be also explained by DNA repair. It appears that the TGF-β RII
deficiency does not facilitate a proliferative reaction after NMDA lesion.
4.6 Constriction of the effects to the central retina
All effects of the Smad7 deficiency are found in the central retina. This could be
due to the differentiation of the retina that starts at the center around the optic
nerve head, and ends at the periphery [44]. As discussed above, we assume that
TGF-β has a pro-proliferative effect on stem cells during certain, early stages of
development. If the cells of the retina react to the alteration in signaling in this
defined time frame, this could affect a certain part of the retinal cells, for example
only the cells of the central retina, assuming that these cells are in the right stage
of growth and differentiation to react to the signal at this point in time.
A second possibility could be that receptors like TGF-β RI or RII are more
intensely expressed in the central retina than in the periphery. This could lead
to a dose dependent effect of TGF-β. Working with the CTGF overexpressing
mice we saw a dose dependent thickening that started around the optic nerve
head and spread to the whole retina with increased expression of CTGF. In the
mouse model with an induceable homozygous deletion of TGF-β RII we could see
that the effect of the thinned retina was not constricted to the central retina like
in the Smad7 deficient mice. Considering these facts, it is well possible that in
a mouse model with an induceable homozygous deletion of Smad7, the effect on
thickening and proliferation would not be restricted to the area around the optic
nerve head. Up to now, however, there is no evidence for an uneven distribution
of the receptors.
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4.7 Outlook
We suppose that a reduced expression of Smad7 and an enhanced TGF-β sig-
naling lead to a thickened retina and an increased number of Mu¨ller glia. Our
results additionally indicate that a Smad7 deficiency causes an increased number
of proliferating cells in the retinae of newborn mice. Together with an elevated
cell number in the adult retina, this could point to an increased self renewal ability
in the retinal progenitor cells leading to delayed differentiation.
Besides the effects on proliferation and cell number, a raised immunoreactivity
for Nestin could be seen in adult Smad7 deficient mice. Whether or not the Nestin
expression is a direct effect of the altered TGF beta pathway is still unclear.
Injections of TGF beta/PBS in the eyes of wildtype animals could help to answer
this question.
We assume that there is a direct connection between the increased Nestin ex-
pression in the central retina in adult animals, and the increased proliferation
in newborn Smad7 deficient mice, that leads to a thickening in this part of the
retina.
In myoblasts, Nestin is known to modulate the cleavage of p35, an activator
protein of Cdk5 (Cyclin dependent kinase) to its degradation resistant form p25.
Therefore it is able to halt myoblast differentiation by inhibition of the continu-
ing activation of Cdk5 by p25 [126]. The same mechanism could also affect the
differentiation of the progenitor cells in the mouse retina.
To verify this hypothesis regarding our mouse models, further experiments need
to be conducted. Experiments with cultured Mu¨ller glia turned out to be difficult
in this case, as the Nestin expression in Mu¨ller glia cells appears to rise heavily in
culture after isolation. Instead it would be possible to work with freshly isolated
progenitor cells from newborn Smad7 deficient mice with an induceable homozy-
gous deletion of Smad7. Using this material it could be possible to check the cell
cycle status by FACS analysis or do western blots on p35 and p25 to see if there
is any difference in expression. For this experiments we already started breed-
ing CAG Cre x Smad7fl/fl mice to achieve a Tamoxifen-induceable homozygous
deletion of Smad7 in the eye.
One other question remained unanswered. The Smad7 deficiency had an effect
on the proliferation of the embryonic stem cell population, but could not cause
proliferation of the Mu¨ller glia cells post-lesion. This is possibly again due to
the TGF-β signaling having different effects on embryonic compared to adult
stem/progenitor cells. It is possible that other signaling pathways have to be
activated or repressed in addition, to achieve an effect. An experiment combining
an EGF/FGF injection with a lesion in Smad7 deficient mice or animals with an
induceable homozygous deletion would be a promising possibility. It also remains
to be tested if a homozygous deletion of Smad7 in the retina causes a reaction
after a lesion.

Chapter 5
Summary
There is evidence that Mu¨ller glia cells have some of the same characteristics
as neuronal progenitor cells. Still, they do not proliferate under physiological
conditions in the adult mammalian retina. As TGF-β is known to impair prolif-
eration in the brain [100], we formulated the hypothesis that the progenitor cell
populations in the retina could be also be influenced by TGF-β signaling.
Based on our results we were able to conclude that TGF-β signaling has a sig-
nificant effect on the retina: It influences the proliferation during the development
of the central retina, but does not provoke proliferation in the normal and injured
adult retina when altered. To investigate the effects of the TGF-β pathway on
Mu¨ller glia cells and their precursors, we studied three different mouse models:
Smad7 deficient mice with enhanced TGF-β signaling, and mice with a hetero-
zygous respectively induceable homozygous deletion of TGF-β RII as models for
diminished TGF-β signaling. Smad7 deficient mice showed a significantly thick-
ened inner and outer nuclear layer near the optic nerve head, and a significantly
elevated number of Mu¨ller glia cells in the central retina. In mice carrying the
induceable homozygous deletion of TGF-β RII, a slight, but significant thinning
of the retina could be detected.
To evaluate the cause of the thickened retina in the Smad7 deficient mice, the
rates of proliferation and apoptosis were measured by BrdU staining at P4 and
TUNEL-labeling at P8. In these studies the Smad7 deficient mice showed an
increased proliferation in the central retina at P4, which could apparently be
the reason for the thickening of the retina, while the rate of apoptosis remained
unchanged. Reduced expression of Smad7 also increased the expression of Nestin,
a progenitor cell marker, in the central retina. This might well be closely connected
to the increased proliferation in the central retina. To study the effect of altered
TGF-β signaling on the proliferative reaction in the adult lesioned retina, we used
NMDA injections on Smad7 and TGF-β RII deficient mice. Smad7 deficient mice
showed no BRDU positive cells after NMDA injection, while in TGF-β deficient
mice sporadic BRDU positive cells were found in the outer nuclear layer one day
after injection. Most likely, this effect is due to DNA repair.
In a nutshell, the results show that TGF-β influences the proliferation in the
central retina during development, while proliferation is absent in the normal or
injured adult retina.
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